Metabolism of Carbohydrates - Medical Biochemistry

Concept & Definition
• Carbohydrates are polyhydroxy aldehydes or ketones and their derivatives, or compounds that yield them on hydrolysis.
• They are built from C, H, O; the empirical formula often approximates Cₙ(H₂O)ₙ, but important exceptions exist (e.g., deoxysugars, aminosugars).
• In humans, they provide immediate energy, form structural matrices (ECM glycosaminoglycans), and mediate cell recognition/signaling (glycoconjugates).

Core Chemical Features
• Functional groups: Multiple –OH groups plus a carbonyl (–CHO in aldoses; C=O at C-2 in ketoses).
• Reactivity anchor: The anomeric carbon (carbonyl carbon in open chain; C-1 in aldoses, C-2 in ketoses) is chemically most reactive and defines many properties (reducing nature, glycosidic bond formation).
• Hydrophilicity: Dense hydrogen bonding makes sugars water-soluble and influences sweetness, osmotic effects, and colloid behavior.

Stereochemistry Essentials
• Chirality: Most monosaccharides contain multiple chiral centers → many stereoisomers with distinct biology (enzymes are highly stereospecific).
• D/L series: Assigned by configuration of the penultimate carbon (furthest chiral center from carbonyl) relative to D-glyceraldehyde; D-sugars predominate in humans.
• Fischer vs Haworth: Fischer shows linear stereochemistry; Haworth depicts cyclic forms (pyranose/furanose). Both are the same molecule represented differently.

Isomerism You Must Master
• Constitutional (structural) isomers: Same formula, different connectivity (e.g., glucose vs fructose).
• Enantiomers: Non-superimposable mirror images (D-glucose vs L-glucose). Biological systems prefer one enantiomer.
• Diastereomers: Stereoisomers not mirror images (D-glucose vs D-mannose).
• Epimers: Differ at one specific chiral center (glucose–mannose at C-2; glucose–galactose at C-4).
• Anomers: Differ at the anomeric carbon after cyclization → α (anomeric –OH down in D-pyranoses) vs β (–OH up).
• Tautomers: Aldose ↔ ketose interconversion via enediol intermediate under alkaline conditions (clinical impact on reducing tests and lab reactions).

From Open Chain to Cyclic Forms
• Hemiacetal/hemiketal formation: Intramolecular reaction of carbonyl with a distal –OH creates rings.
• Ring size:
• Pyranose (6-membered) is common for glucose (β-D-glucopyranose is the major solution form).
• Furanose (5-membered) is frequent for fructose (β-D-fructofuranose in sucrose).
• Anomeric effect: Substituents at the anomeric center show axial stabilization in some contexts—relevant in glycoside stability and conformation.

Mutarotation (High-Yield Concept)
• In aqueous solution, α and β anomers interconvert via the open-chain form to reach an equilibrium specific rotation (e.g., D-glucose: α ≈ +112°, β ≈ +18.7°, equilibrium ≈ +52.7°).
• Mutarotation explains changes in optical rotation over time and underpins differences in reducing behavior and enzyme specificity.

Conformations in Solution
• Chair conformations (for pyranoses): Substituents prefer equatorial positions to minimize steric hindrance; β-D-glucose gains stability as all bulky groups are equatorial.
• Furanose puckers: Conformational flexibility influences recognition by enzymes and lectins.

Chemical Reactions of Monosaccharides
• Oxidation
• Aldehyde → aldonic acid (e.g., gluconic acid).
• Primary alcohol (C-6) → uronic acid (e.g., glucuronic acid in bilirubin conjugation).
• Complete oxidation → aldaric acids (e.g., glucaric).
• Reduction
• Carbonyl → sugar alcohols (alditols): glucose→sorbitol, galactose→dulcitol.
• Pathology link: Sorbitol accumulation in lens, retina, nerve (polyol pathway) contributes to diabetic cataract/neuropathy.
• Esterification
• Phosphate esters (glucose-6-phosphate, fructose-1,6-bisphosphate) trap sugars intracellularly and regulate glycolysis/glycogenesis.
• Ether formation
• Glycosides via reaction with alcohols at the anomeric carbon → forms O-glycosidic bonds (non-reducing if anomeric carbon is locked).
• Isomerization
• Base-catalyzed aldose↔ketose via enediol (basis of Seliwanoff differences and Benedict reactivity).

• Osazone formation
• Reaction with phenylhydrazine yields diagnostic crystals: glucose, mannose, fructose → needle/broomstick; maltose → sunflower; lactose → puff-ball.
• Maillard (non-enzymatic glycation)
• Carbonyl of reducing sugars reacts with amino groups of proteins → Schiff base → Amadori products → AGEs; clinical marker HbA1c reflects average glycemia.

Analytical/Bedside Reactions
• Reducing sugars reduce Cu²⁺ → Cu₂O (brick-red) in Benedict/Fehling; Ag⁺ → Ag⁰ in Tollen. Presence needs clinical interpretation (e.g., glucosuria vs other sugars).
• Barfoed distinguishes monosaccharides (faster reduction) from disaccharides in acidic medium.
• Seliwanoff: Ketoses react faster (red color) than aldoses.
• Bial (orcinol): Pentoses give blue-green color (ribose detection).

Grand Classification Overview
• By size (degree of polymerization)
• Monosaccharides: Single unit (glucose, fructose, galactose, ribose).
• Oligosaccharides: 2–10 units; disaccharides are most common (maltose, lactose, sucrose, trehalose).
• Polysaccharides: >10 units; either homopolysaccharides (one monomer) or heteropolysaccharides (mixed monomers).

• By carbonyl class
• Aldoses (–CHO): glucose, galactose, ribose.
• Ketoses (C=O at C-2): fructose, ribulose, xylulose.

• By carbon number
• Trioses: glyceraldehyde (aldose), dihydroxyacetone (ketose) — pivotal in glycolysis.
• Tetroses: erythrose (PPP and biosynthesis).
• Pentoses: ribose (RNA), deoxyribose (DNA), ribulose-5-P (PPP).
• Hexoses: glucose, fructose, galactose, mannose — central to diet and metabolism.
• Heptoses: sedoheptulose (PPP interconversions).

• By reducing property
• Reducing sugars: free anomeric carbon in open/α,β equilibrium (glucose, lactose, maltose).
• Non-reducing sugars: anomeric carbons tied in glycosidic bond (sucrose, trehalose).

Biologically Important Monosaccharide Derivatives
• Deoxysugars: 2-deoxyribose in DNA; L-fucose in blood group antigens.
• Amino sugars: D-glucosamine, D-galactosamine in GAGs and glycoproteins.
• Uronic acids: D-glucuronic acid aids detoxification (bilirubin, drugs).
• Sugar acids: sialic acids (N-acetylneuraminic acid) at glycoprotein termini regulate half-life and cell interactions.
• Sugar alcohols: sorbitol, mannitol, xylitol (osmotic roles; clinical use as osmotic agents/sweeteners).

Oligosaccharides & Disaccharides (Linkages and Properties)
• Maltose
• Composition: Glc-α(1→4)-Glc.
• Reducing (free anomeric carbon on one glucose).
• Source from starch digestion (amylase).
• Lactose
• Composition: Gal-β(1→4)-Glc.
• Reducing. Requires lactase; deficiency → lactose intolerance (osmotic diarrhea, bloating).
• Sucrose
• Composition: Glc-α(1→2)-β-Fru.
• Non-reducing (both anomeric carbons engaged) → negative Benedict test despite sweetness.
• Trehalose
• Composition: Glc-α(1→1)-α-Glc.
• Non-reducing; found in fungi/insects; high stability.

Polysaccharides — Storage vs Structural
• Homopolysaccharides (Storage)
• Starch (plants)
• Amylose: linear α(1→4); forms helical coils; gives blue with iodine.
• Amylopectin: α(1→4) chains with α(1→6) branches every ~24–30 residues; gives reddish-purple with iodine.
• Glycogen (animals)
• Similar to amylopectin but more frequent branches (~8–12 residues) → rapid mobilization; iodine gives brown.
• Stored in liver (maintains blood glucose) and muscle (local energy).
• Homopolysaccharides (Structural)
• Cellulose: β(1→4)-Glc linear chains; no iodine color; humans lack cellulase → dietary fiber.
• Chitin: β(1→4)-N-acetylglucosamine; arthropod exoskeleton, fungal cell walls.
• Dextrans/Inulin: microbial/plant storage and clinical uses (e.g., inulin for GFR estimation).

• Heteropolysaccharides (Glycosaminoglycans, GAGs)
• Built from repeating uronic acid + hexosamine disaccharides; highly anionic, hydrophilic → gel-forming, shock-absorbing ECM.
• Hyaluronic acid: D-glucuronic acid + N-acetylglucosamine; non-sulfated, enormous size; synovial fluid, vitreous humor.
• Chondroitin sulfate: cartilage; tensile strength.
• Dermatan sulfate: skin, valves, vessels.
• Keratan sulfate: cornea, cartilage.
• Heparan sulfate/Heparin: highly sulfated; heparin is a potent anticoagulant (activates antithrombin).

Glycoconjugates — Functional Integration
• Glycoproteins
• Protein with oligosaccharide chains (N-linked to Asn via GlcNAc; O-linked to Ser/Thr via GalNAc).
• Roles in hormone receptors, enzymes, immunity (IgG Fc glycosylation), mucins.
• Glycolipids
• Lipids with carbohydrate headgroups; include gangliosides and globosides; form myelin components and ABO blood group determinants.
• Proteoglycans
• Core protein heavily decorated with GAG chains; create hydrated gels for compression resistance in cartilage.

Reducing vs Non-Reducing Nature — Why It Matters
• Reducing sugars possess a free anomeric carbon capable of opening to aldehyde/ketone → reduce metal ions and glycate proteins (HbA1c).
• Non-reducing sugars lock both anomeric carbons in glycosidic bonds → chemically less reactive in redox tests (classic sucrose example).
• Clinical interpretation of a positive Benedict test in urine must differentiate glucosuria (diabetes), galactosuria (galactosemia), or fructosuria (essential fructosuria).

Transport & Utilization Notes (Clinical Angle)
• GLUT transporters:
• GLUT-1/3: basal uptake (brain, RBCs).
• GLUT-2: liver, β-cells (bidirectional, high Km).
• GLUT-4: insulin-responsive (muscle, adipose).
• SGLT-1/2: Na⁺-dependent active uptake (intestine; renal proximal tubule).
• Transporter distribution explains hypoglycemia vulnerability (brain), SGLT-2 inhibitor glucosuria, and dietary absorption physiology.

High-Yield Clinical Correlations
• Diabetes mellitus
• Chronic hyperglycemia → increased non-enzymatic glycation (HbA1c), polyol pathway flux (sorbitol in lens, nerves), AGEs → micro/macro-vascular injury.
• Lactose intolerance
• Lactase deficiency → undigested lactose exerts osmotic load, fermented by colonic bacteria → bloating, diarrhea; positive reducing sugars in stool.
• Hereditary fructose intolerance
• Aldolase B deficiency; ingestion of fructose/sucrose leads to phosphate trapping, ATP depletion, hypoglycemia, vomiting, liver dysfunction; avoidance is curative.
• Essential fructosuria
• Fructokinase deficiency; benign fructose in urine (reducing).
• Classic galactosemia
• GALT deficiency; galactose-1-phosphate buildup → jaundice, vomiting, E. coli sepsis, cataracts; manage with galactose/lactose restriction.
• Glycogen storage diseases
• Abnormal glycogen quantity/structure → hepatic hypoglycemia, myopathy, cardiomegaly depending on enzyme defect.
• Mucopolysaccharidoses
• Lysosomal enzyme defects impair GAG degradation → coarse facies, organomegaly, skeletal abnormalities, ± CNS involvement (e.g., Hurler, Hunter).
• Heparin therapy
• GAG derivative with immediate anticoagulant effect; monitored clinically to prevent bleeding.

Exam-Focused Disaccharide & Test Pearls
• Sucrose is non-reducing because both anomeric carbons are linked (α1↔2β).
• Lactose is reducing and needs lactase (brush border).
• Maltose is reducing; intermediate in starch digestion.
• Osazone: glucose, fructose, mannose → identical needle/broomstick crystals (same configuration at C-3 onward).
• Seliwanoff: ketoses react faster (deep cherry-red) than aldoses.

Putting It All Together — Quick Visual Map (Textual)
• Monosaccharides → building blocks; chemistry determined by carbonyl class, number of carbons, stereochemistry.
• Cyclization → defines α/β anomers, mutarotation, reducing ability.
• Glycosidic bonds → link sugars: type of carbon, α/β configuration, and branching dictate digestibility, function, and test behavior.
• Polysaccharide architecture → storage (α-linked, digestible) vs structural (β-linked, indigestible to humans).
• Derivatives & glycoconjugates → expand roles to detoxification, cell signaling, ECM mechanics, hemostasis.

High-Yield Summary (Memory Anchors)
• “Aldose vs Ketose” decides Seliwanoff kinetics; “Free anomeric carbon” decides reducing tests.
• “α for storage, β for structure”: α-links (starch/glycogen) digestible; β-links (cellulose/chitin) structural.
• “Anomeric carbon is king”: chemistry, linkage, and HbA1c originate here.
• “GAGs love water”: sulfated, anionic, shock-absorbing ECM gels; defects → mucopolysaccharidoses.

? Introduction to Carbohydrate Digestion

Carbohydrates in our diet are predominantly in the form of polysaccharides (starch from plants, glycogen from animal sources), disaccharides (sucrose, lactose, maltose), and small amounts of monosaccharides (glucose, fructose, galactose).
Digestion involves enzymatic hydrolysis of glycosidic bonds to yield monosaccharides — the only form that can be absorbed into the bloodstream.

Carbohydrate digestion begins in the mouth, continues in the small intestine, and is completed by brush-border enzymes. No carbohydrate digestion occurs in the stomach due to the acidic pH.

? Overview of the Process

• Goal: Break down complex carbohydrates → monosaccharides (glucose, galactose, fructose).

• Enzymes involved: Glycosidases/amylases, disaccharidases (maltase, lactase, sucrase, isomaltase, trehalase).

• Special feature: Human enzymes hydrolyze α-glycosidic linkages but not β-glycosidic linkages in cellulose (dietary fiber).

? Digestion in the Mouth — Initiation Phase

Enzyme: Salivary α-amylase (ptyalin)

• Secreted by parotid glands.

• Acts at neutral to slightly alkaline pH (6.7–7.0); inactivated in acidic stomach.

• Randomly hydrolyzes internal α(1→4) glycosidic bonds of starch and glycogen.

• Products: Maltose, maltotriose, and α-limit dextrins (branched fragments containing α(1→6) linkages).

• Clinical note: Amylase measurement in serum/urine helps diagnose acute pancreatitis (though salivary amylase rises in mumps).

? Digestion in the Stomach — No Direct Carbohydrate Breakdown

• pH ≈ 1–2 inactivates salivary amylase within 15–30 minutes after entry into stomach.

• Mechanical churning mixes food with gastric juice → forms chyme.

• No carbohydrate-specific enzymes in gastric juice; however, acid hydrolysis of glycosidic bonds is minimal.

• The stomach acts as a holding chamber, releasing chyme gradually into the small intestine for optimal enzyme action.

? Digestion in the Small Intestine — Major Phase

Duodenum & Jejunum — Pancreatic Phase

Enzyme: Pancreatic α-amylase

• Secreted by pancreas in active form (unlike proteases, which are zymogens).

• Optimum pH: 6.7–7.0.

• Requires chloride ions for activity.

• Hydrolyzes internal α(1→4) bonds of starch/glycogen to form:

  • Maltose (2 glucose units)

  • Maltotriose (3 glucose units)

  • α-limit dextrins (contain branching α(1→6) bonds unhydrolyzed by amylase)

• Cannot hydrolyze:

  • α(1→6) bonds (branch points in amylopectin, glycogen)

  • Terminal α(1→4) bonds

  • β(1→4) bonds (cellulose)

Brush-Border Phase — Final Breakdown to Monosaccharides

Located in the microvilli membrane of small intestinal enterocytes.
Key Enzymes & Their Actions:

• Maltase: Hydrolyzes maltose → 2 glucose.

• Sucrase: Hydrolyzes sucrose → glucose + fructose.

• Lactase (β-galactosidase): Hydrolyzes lactose → glucose + galactose.

• Isomaltase (α-dextrinase): Hydrolyzes α(1→6) bonds in α-limit dextrins.

• Trehalase: Hydrolyzes trehalose → 2 glucose (important in fungi/insects).

These enzymes act synergistically to ensure complete hydrolysis of dietary carbohydrates to absorbable monosaccharides.

? Absorption of Monosaccharides

Mechanisms:

• Glucose & Galactose: Absorbed by secondary active transport via SGLT-1 (sodium-glucose co-transporter) on the apical membrane.

• Fructose: Absorbed by facilitated diffusion via GLUT-5.

• All monosaccharides exit enterocytes into portal circulation via GLUT-2 on the basolateral membrane.

Transporters & Clinical Notes:

• SGLT-1 deficiency → glucose-galactose malabsorption (osmotic diarrhea in infants; improved on fructose feeding).

• GLUT-5 deficiency → impaired fructose absorption (fructose malabsorption → bloating, diarrhea).
  
  ? Clinical Correlations

  • Lactase deficiency: Most common disaccharidase deficiency → lactose intolerance (bloating, cramps, diarrhea). Stool is acidic with positive reducing sugars.

  • Sucrase-isomaltase deficiency: Rare congenital disorder → intolerance to sucrose and starch.

  • Pancreatic insufficiency: Seen in chronic pancreatitis, cystic fibrosis; leads to maldigestion and steatorrhea.

  • Celiac disease: Villous atrophy → reduced brush-border enzyme activity → secondary disaccharidase deficiency.

  • Oral rehydration therapy: Utilizes SGLT-1 co-transport (glucose + sodium) to promote water absorption in diarrheal diseases.

? Introduction to Carbohydrate Absorption

Carbohydrate absorption is the process by which the monosaccharides produced from digestion — glucose, galactose, and fructose — enter the bloodstream from the intestinal lumen.
Only monosaccharides can be absorbed; polysaccharides and disaccharides must be hydrolyzed before absorption.

Absorption occurs mainly in the duodenum and proximal jejunum through specialized membrane transporters located on the apical (luminal) and basolateral sides of enterocytes.

? Forms of Carbohydrates Absorbed

• Glucose: Major product from starch/glycogen digestion.

• Galactose: Mainly from lactose hydrolysis.

• Fructose: From sucrose and fruit sugars.

• Small amounts of pentoses (e.g., xylose, arabinose) may also be absorbed.

? Mechanisms of Absorption

1. Apical Membrane Transport (Lumen → Enterocyte)

a) Sodium-dependent glucose transport (SGLT-1)

• Transports: Glucose & Galactose.

• Mechanism: Secondary active transport — uses the Na⁺ gradient maintained by the Na⁺/K⁺-ATPase pump (on basolateral side).

• Steps:

  1. Na⁺ binds to SGLT-1 from the lumen.

  2. Glucose or galactose binds to the transporter.

  3. Both are co-transported into the enterocyte.

  4. Na⁺ is actively pumped out of the cell into blood by Na⁺/K⁺-ATPase, maintaining the gradient.

• Clinical correlation: Basis of Oral Rehydration Therapy (ORT) — sodium and glucose given together enhance water absorption.

b) Facilitated diffusion of fructose (GLUT-5)

• Transports: Fructose (specific).

• Mechanism: Facilitated diffusion (passive, no energy).

• Clinical note: GLUT-5 deficiency causes fructose malabsorption → bloating, diarrhea.

2. Basolateral Membrane Transport (Enterocyte → Blood)

GLUT-2 transporter

• Transports glucose, galactose, and fructose out of the enterocyte into portal circulation.

• Mechanism: Facilitated diffusion.

• High-capacity and low-affinity — ideal for post-meal rapid sugar exit into blood.
  
  ? Physiological Regulation
  

  • Postprandial state: High luminal glucose → GLUT-2 may be transiently inserted into apical membrane to enhance uptake.

  • Hormonal influences: Insulin mainly regulates glucose utilization in target tissues, not absorption.

  • Adaptation: Increased carbohydrate intake can upregulate transporter expression.

  ? Clinical Correlations

  1. Glucose-Galactose Malabsorption

  • Cause: Mutations in SGLT-1.

  • Symptoms: Severe osmotic diarrhea in newborns fed glucose/galactose.

  • Management: Replace with fructose-based formula (absorbed via GLUT-5).

  2. Fructose Malabsorption

  • Cause: GLUT-5 deficiency.

  • Symptoms: Bloating, abdominal discomfort, diarrhea after fructose ingestion.

  • Management: Restrict dietary fructose.

  3. Secondary Disaccharidase Deficiencies

  • Cause: Loss of brush-border enzymes (e.g., in celiac disease, gastroenteritis).

  • Effect: Disaccharides not digested → no monosaccharide absorption → osmotic diarrhea.

  4. Diabetes Mellitus and ORS

  • ORS exploits SGLT-1 co-transport: Na⁺-glucose uptake pulls water into enterocytes → effective rehydration even during diarrheal illness.

  ? High-Yield Exam Points

  • Only monosaccharides are absorbed into blood.

  • SGLT-1 is active transport (Na⁺-dependent), GLUT-5 is passive, GLUT-2 is passive.

  • Oral Rehydration Therapy works because SGLT-1 function is preserved in most diarrheal diseases (including cholera).

  • Lactase deficiency does not impair SGLT-1 — the problem is digestion, not transport.

  • Portal vein delivers absorbed sugars directly to the liver for metabolism or storage.

? Introduction to Glycolysis

• Definition: Glycolysis is the metabolic pathway that converts glucose → pyruvate (or lactate in anaerobic conditions), generating ATP and NADH.

• Location: Cytoplasm of all cells.

• Significance:

  • Primary energy source for RBCs (no mitochondria) and CNS (under normal conditions).

  • First step in glucose oxidation before TCA cycle and oxidative phosphorylation.

  • Can function aerobically (with oxygen) or anaerobically (without oxygen).

• Overall Reaction (Aerobic):

  Glucose+2NAD++2ADP+2Pi→2Pyruvate+2NADH+2H++2ATP+2H2OGlucose + 2 NAD^+ + 2 ADP + 2 P_i → 2 Pyruvate + 2 NADH + 2 H^+ + 2 ATP + 2 H_2OGlucose+2NAD++2ADP+2Pi​→2Pyruvate+2NADH+2H++2ATP+2H2​O
  

? Phases of Glycolysis

• Preparatory (Investment) Phase: Glucose is phosphorylated and split — consumes ATP.

• Payoff Phase: Generates ATP and NADH — net gain of energy.

? Step-by-Step Reactions

Step 1 — Glucose → Glucose-6-phosphate (G6P)

• Enzyme: Hexokinase (most tissues) / Glucokinase (liver, β-cells)

• Cofactor: Mg²⁺ required.

• Reaction type: Phosphorylation at C-6.

• ATP use: 1 ATP consumed.

• Regulation:

  • Hexokinase: Inhibited by G6P (feedback).

  • Glucokinase: Induced by insulin; high Km and Vmax (active at high glucose).

• Clinical note: Glucokinase deficiency → hyperglycemia (MODY type 2).

Step 2 — G6P → Fructose-6-phosphate (F6P)

• Enzyme: Phosphoglucose isomerase.

• Reaction type: Isomerization (aldose → ketose).

• Significance: Prepares for second phosphorylation at C-1.

Step 3 — F6P → Fructose-1,6-bisphosphate (F1,6BP)

• Enzyme: Phosphofructokinase-1 (PFK-1)

• ATP use: 1 ATP consumed.

• Rate-limiting step: This is the committed step of glycolysis.

• Regulation:

  • Activated by: AMP, ADP, fructose-2,6-bisphosphate.

  • Inhibited by: ATP, citrate, low pH.

• Clinical note: Defects here are rare; PFK-1 activity is enhanced by insulin.

Step 4 — F1,6BP → DHAP + G3P

• Enzyme: Aldolase A (muscle/RBCs), B (liver), C (brain).

• Reaction type: Aldol cleavage.

• Clinical note: Aldolase B deficiency causes hereditary fructose intolerance.

Step 5 — DHAP ⇌ G3P

• Enzyme: Triose phosphate isomerase.

• Significance: Converts DHAP into G3P so both products of step 4 can proceed through glycolysis.

Step 6 — G3P → 1,3-bisphosphoglycerate (1,3-BPG)

• Enzyme: Glyceraldehyde-3-phosphate dehydrogenase (G3PDH).

• Cofactor: NAD⁺ → NADH (aerobic: NADH → ATP via ETC; anaerobic: NADH reoxidized by lactate dehydrogenase).

• Reaction type: Oxidation + phosphorylation (inorganic Pi, not ATP).

• Clinical note: Inhibited by arsenate (competes with Pi).

Step 7 — 1,3-BPG → 3-phosphoglycerate (3PG)

• Enzyme: Phosphoglycerate kinase.

• ATP yield: 1 ATP per molecule (substrate-level phosphorylation).

• Reversibility: Yes.

• Clinical note: In RBCs, 1,3-BPG can be diverted to 2,3-BPG via bisphosphoglycerate mutase (oxygen delivery regulation).

Step 8 — 3PG → 2-phosphoglycerate (2PG)

• Enzyme: Phosphoglycerate mutase.

• Cofactor: Requires 2,3-BPG as primer in RBCs.

Step 9 — 2PG → Phosphoenolpyruvate (PEP)

• Enzyme: Enolase.

• Inhibitor: Fluoride (used in blood glucose sample preservation to inhibit glycolysis).

Step 10 — PEP → Pyruvate

• Enzyme: Pyruvate kinase.

• ATP yield: 1 ATP per molecule (substrate-level phosphorylation).

• Regulation:

  • Activated by: Fructose-1,6-bisphosphate (feed-forward).

  • Inhibited by: ATP, alanine.

• Clinical note: Pyruvate kinase deficiency → hemolytic anemia (ATP depletion in RBCs).

⚡ Energetics of Glycolysis

Aerobic Glycolysis (per 1 glucose → 2 pyruvate)

• ATP used: 2 (Step 1 & Step 3).

• ATP generated (substrate-level): 4 (Step 7 & Step 10).

• NADH generated: 2 (Step 6).

• Net ATP:

  • NADH → ATP via ETC:

    • Glycerol-3-phosphate shuttle: 2 NADH → 4 ATP.

    • Malate-aspartate shuttle: 2 NADH → 6 ATP.

  • Total ATP yield:

    • G3P shuttle: 6 ATP net.

    • Malate-Asp shuttle: 8 ATP net.

Anaerobic Glycolysis (e.g., RBCs, exercising muscle)

• Pyruvate → lactate via lactate dehydrogenase (regenerates NAD⁺).

• Only substrate-level ATP is counted.

• Net ATP: 2 ATP per glucose.

? Clinical Correlations

• Pyruvate kinase deficiency: RBCs depend entirely on glycolysis → ATP depletion → loss of membrane function → hemolysis.

• Lactic acidosis: Excess anaerobic glycolysis due to hypoxia, mitochondrial defects, or pyruvate dehydrogenase deficiency.

• Fluoride in blood collection tubes: Inhibits enolase to prevent post-collection glycolysis.

• Cancer metabolism: Tumor cells often exhibit high glycolysis even in oxygen (Warburg effect) — basis for PET scanning using fluorodeoxyglucose (FDG).

? Introduction

In biochemical pathways, certain steps are irreversible — they proceed in one direction under physiological conditions because they have a large negative free energy change (ΔG).
In glycolysis, these irreversible steps act as metabolic control points and are heavily regulated to match cellular energy needs.

                                                                  ? The 3 Irreversible Steps of Glycolysis

Step 1 — Hexokinase / Glucokinase Reaction

Reaction:

Glucose+ATP→Glucose−6−phosphate+ADPGlucose + ATP → Glucose-6-phosphate + ADPGlucose+ATP→Glucose−6−phosphate+ADP

• Hexokinase (in most tissues):

  • Low Km (high affinity) → active even at low glucose.

  • Low Vmax → saturates quickly.

  • Inhibited by G6P (product inhibition).

• Glucokinase (in liver & β-cells):

  • High Km (low affinity) → active only when glucose is abundant (post-meal).

  • High Vmax → clears large glucose load.

  • Induced by insulin; inhibited indirectly by fructose-6-phosphate via glucokinase regulatory protein (GKRP).

Control Significance:

• Prevents trapping glucose in cells when not needed.

• Liver glucokinase allows storage of excess glucose as glycogen.

Clinical note: Glucokinase mutations → MODY type 2 (mild fasting hyperglycemia).

Step 3 — Phosphofructokinase-1 (PFK-1) Reaction

Reaction:

Fructose−6−phosphate+ATP→Fructose−1,6−bisphosphate+ADPFructose-6-phosphate + ATP → Fructose-1,6-bisphosphate + ADPFructose−6−phosphate+ATP→Fructose−1,6−bisphosphate+ADP

• Most important control point of glycolysis (rate-limiting step).

• Allosteric regulation:

  • Activators:

    • AMP, ADP (signal low energy)

    • Fructose-2,6-bisphosphate (powerful activator, produced by PFK-2 under insulin control)

  • Inhibitors:

    • ATP (signals high energy state)

    • Citrate (signals abundant biosynthetic precursors)

    • Low pH (protects against lactic acidosis in muscle)

Hormonal regulation via PFK-2/FBPase-2 system:

• Insulin (fed state) → activates PFK-2 → ↑ F2,6BP → stimulates PFK-1 → ↑ glycolysis.

• Glucagon (fasting state) → activates FBPase-2 → ↓ F2,6BP → inhibits PFK-1 → ↓ glycolysis (promotes gluconeogenesis).

Clinical note:

• Tumor cells often have high PFK-1 activity (Warburg effect).

• AMP deficiency or fructose-2,6-bisphosphate deficiency impairs glycolysis.

Step 10 — Pyruvate Kinase Reaction

Reaction:

Phosphoenolpyruvate+ADP→Pyruvate+ATPPhosphoenolpyruvate + ADP → Pyruvate + ATPPhosphoenolpyruvate+ADP→Pyruvate+ATP

• Feed-forward activation by fructose-1,6-bisphosphate.

• Allosteric inhibitors: ATP, alanine (signals enough energy and building blocks).

• Hormonal regulation (liver):

  • Insulin activates pyruvate kinase (dephosphorylated form).

  • Glucagon inactivates it via phosphorylation (prevents glycolysis during fasting).

Clinical note:

• Pyruvate kinase deficiency → ↓ ATP in RBCs → impaired Na⁺/K⁺ pump → hemolytic anemia.

⚙️ Integrated Regulation of Glycolysis

1. Energy Charge Control

• High ATP → inhibits PFK-1 & pyruvate kinase.

• High AMP/ADP → activates PFK-1 & indirectly glycolysis.

2. Substrate Availability

• Glucose uptake via GLUT transporters influences glycolytic rate.

• In muscle, GLUT-4 is insulin- and exercise-sensitive.

3. Allosteric Metabolites

• AMP & ADP: signal low energy → stimulate glycolysis.

• Citrate: signals TCA cycle sufficiency → inhibits glycolysis.

• Fructose-2,6-bisphosphate: most potent activator of PFK-1 in liver.

4. Hormonal Regulation

• Insulin (fed state): increases glucokinase, PFK-1, pyruvate kinase activity → ↑ glycolysis.

• Glucagon (fasting): decreases these enzymes' activity via phosphorylation → ↓ glycolysis, ↑ gluconeogenesis.

5. Oxygen Availability

• Anaerobic conditions (hypoxia, intense exercise): pyruvate → lactate via LDH; glycolysis rate increases to compensate for low ATP yield.

? High-Yield Clinical Correlations

• Glucokinase deficiency → mild fasting hyperglycemia (MODY type 2).

• PFK-1 deficiency (Tarui disease) → exercise intolerance, hemolytic anemia, myoglobinuria.

• Pyruvate kinase deficiency → chronic hemolytic anemia; severity depends on residual enzyme activity.

• Cancer metabolism: Oncogenes upregulate glycolytic enzymes (esp. PFK-1, hexokinase II) to support rapid cell division.

? Introduction

The Pyruvate Dehydrogenase Complex (PDC) is a large, multi-enzyme system located in the mitochondrial matrix.
Its main role is to convert pyruvate (end product of glycolysis) into acetyl-CoA, which enters the TCA cycle for complete oxidation to CO₂ and ATP.
This is a link reaction between glycolysis and the TCA cycle and is irreversible under physiological conditions.

This reaction is crucial because pyruvate is at a metabolic crossroads — it can be:

• Converted to lactate (anaerobic glycolysis)

• Converted to oxaloacetate (gluconeogenesis)

• Converted to acetyl-CoA (oxidative metabolism via PDC)
  

                                                                                     ? Overall Reaction

Pyruvate + NAD⁺ + CoA → Acetyl-CoA + NADH + H⁺ + CO₂

This oxidative decarboxylation produces NADH (energy currency) and releases CO₂.

? Structure and Components of the Complex

The PDC consists of three core enzyme components tightly associated in a multienzyme complex, along with five coenzymes.

• E1: Pyruvate dehydrogenase (pyruvate decarboxylase) — requires thiamine pyrophosphate (TPP).

• E2: Dihydrolipoyl transacetylase — requires lipoic acid and Coenzyme A.

• E3: Dihydrolipoyl dehydrogenase — requires FAD and NAD⁺.

? Five Essential Coenzymes and Their Roles

1. Thiamine pyrophosphate (TPP) — derived from vitamin B₁; bound to E1; carries out decarboxylation of pyruvate.

2. Lipoic acid — bound to E2; accepts the hydroxyethyl group from TPP and oxidizes it to an acetyl group.

3. Coenzyme A (CoA-SH) — derived from pantothenic acid (B₅); accepts acetyl group from lipoic acid to form acetyl-CoA.

4. FAD — derived from riboflavin (B₂); bound to E3; reoxidizes reduced lipoic acid.

5. NAD⁺ — derived from niacin (B₃); accepts electrons from FADH₂ to form NADH.

                                                                       ? Stepwise Mechanism of Action

Step 1: Decarboxylation of Pyruvate

• E1 (with TPP) removes CO₂ from pyruvate, forming hydroxyethyl-TPP.

• This step is irreversible and commits pyruvate to oxidation.

Step 2: Oxidation of Hydroxyethyl Group

• The hydroxyethyl group is transferred from TPP to the oxidized form of lipoic acid (on E2), forming acetyl-lipoamide.

Step 3: Formation of Acetyl-CoA

• E2 transfers the acetyl group from acetyl-lipoamide to CoA-SH, forming acetyl-CoA.

Step 4: Regeneration of Oxidized Lipoic Acid

• E3 (with FAD) reoxidizes the reduced lipoamide, producing FADH₂.

Step 5: Regeneration of FAD

• FADH₂ is reoxidized to FAD by NAD⁺, producing NADH + H⁺, which enters the electron transport chain.

⚙️ Regulation of the Pyruvate Dehydrogenase Complex

Allosteric Regulation

• Inhibited by high-energy signals: ATP, NADH, and acetyl-CoA.

• Activated by low-energy signals: ADP, NAD⁺, and CoA-SH.

Covalent Modification (Reversible Phosphorylation)

• A specific PDH kinase phosphorylates E1 → inactivates PDC.

• A PDH phosphatase removes the phosphate → activates PDC.

• PDH kinase is stimulated by ATP, NADH, and acetyl-CoA (signals to turn off the complex when energy is abundant).

• PDH phosphatase is stimulated by Ca²⁺ (important in muscle during exercise to increase acetyl-CoA supply).

Hormonal Regulation

• In liver and adipose tissue, insulin activates PDH phosphatase → stimulates PDC (promotes conversion of glucose to acetyl-CoA for fatty acid synthesis).

• Glucagon generally decreases PDC activity indirectly via kinase activation.

? Clinical Relevance

Thiamine (B₁) Deficiency

• Reduces TPP availability → impairs PDC activity.

• Seen in chronic alcoholism (Wernicke–Korsakoff syndrome) and severe malnutrition.

• Leads to accumulation of pyruvate and lactate → lactic acidosis.

Arsenic Poisoning

• Arsenite binds to lipoic acid, preventing its participation in oxidative decarboxylation.

• Inhibits PDC and α-ketoglutarate dehydrogenase → severe ATP depletion, neurological symptoms.

Pyruvate Dehydrogenase Complex Deficiency

• Rare genetic disorder (usually E1 defect).

• Pyruvate cannot be converted to acetyl-CoA → accumulates and is shunted to lactate → chronic lactic acidosis and neurologic deficits (brain relies heavily on aerobic glucose oxidation).

• Management includes ketogenic diet (high fat, low carbohydrate) and supplementation with cofactors (thiamine, lipoic acid).
  

? High-Yield Points for Exams

• PDC is irreversible — acetyl-CoA cannot be converted back to pyruvate in humans.

• Requires five coenzymes derived from five vitamins:

  • B₁ (TPP), B₂ (FAD), B₃ (NAD⁺), B₅ (CoA), lipoic acid.

• Acts as a metabolic link between glycolysis and the TCA cycle.

• Regulated by both allosteric effectors and covalent phosphorylation.

• Deficiency or inhibition leads to lactic acidosis due to pyruvate shunting to lactate.

? Introduction

The TCA cycle is the central metabolic hub where acetyl-CoA, derived from carbohydrates, fats, and proteins, is oxidized to CO₂, generating high-energy molecules (NADH, FADH₂, GTP) for ATP production via oxidative phosphorylation.

It occurs in the mitochondrial matrix of all aerobic cells and is amphibolic — functioning in both catabolic (energy-producing) and anabolic (biosynthetic) pathways.

? Overall Function

• Oxidizes acetyl-CoA to CO₂.

• Produces NADH and FADH₂ for the electron transport chain.

• Provides intermediates for biosynthesis (amino acids, heme, glucose in gluconeogenesis).
  

                                                                                    ? Overall Reaction

Acetyl-CoA + 3 NAD⁺ + FAD + GDP + Pᵢ + 2 H₂O → 2 CO₂ + 3 NADH + 3 H⁺ + FADH₂ + GTP + CoA-SH

? Step-by-Step Reactions of the TCA Cycle

Step 1: Condensation
Acetyl-CoA (2C) + Oxaloacetate (4C) → Citrate (6C)

• Enzyme: Citrate synthase

• Highly exergonic; driven by thioester bond hydrolysis in acetyl-CoA.

• Regulation: Inhibited by ATP, NADH, succinyl-CoA, citrate.

Step 2: Isomerization
Citrate ↔ Isocitrate

• Enzyme: Aconitase

• Reaction proceeds via cis-aconitate intermediate.

• Inhibited by fluoroacetate (converted to fluorocitrate in vivo — aconitase inhibitor, causing citrate accumulation).

Step 3: Oxidative Decarboxylation
Isocitrate → α-Ketoglutarate + CO₂ + NADH

• Enzyme: Isocitrate dehydrogenase

• First CO₂ released in the cycle.

• Regulation: Activated by ADP, Ca²⁺; inhibited by ATP, NADH.

• Rate-limiting enzyme of the cycle.

Step 4: Oxidative Decarboxylation
α-Ketoglutarate → Succinyl-CoA + CO₂ + NADH

• Enzyme: α-Ketoglutarate dehydrogenase complex (similar to PDH — needs TPP, lipoic acid, CoA, FAD, NAD⁺).

• Regulation: Inhibited by ATP, GTP, NADH, succinyl-CoA; activated by Ca²⁺.

• Second CO₂ released.

Step 5: Substrate-Level Phosphorylation
Succinyl-CoA → Succinate + GTP + CoA-SH

• Enzyme: Succinyl-CoA synthetase (succinate thiokinase).

• GTP can be converted to ATP via nucleoside diphosphate kinase.

Step 6: Oxidation
Succinate → Fumarate + FADH₂

• Enzyme: Succinate dehydrogenase (complex II of ETC, embedded in inner mitochondrial membrane).

• Inhibited by malonate (competitive inhibitor).

Step 7: Hydration
Fumarate → Malate

• Enzyme: Fumarase (fumarate hydratase).

• Reversible addition of water across the double bond.

Step 8: Oxidation
Malate → Oxaloacetate + NADH

• Enzyme: Malate dehydrogenase

• Endergonic under standard conditions, but pulled forward by highly exergonic citrate synthase reaction.

⚡ Energetics of the TCA Cycle (Per Acetyl-CoA)

• 3 NADH → 3 × 3 ATP = 9 ATP (malate-aspartate shuttle basis)

• 1 FADH₂ → 2 ATP

• 1 GTP → 1 ATP equivalent
  Total = 12 ATP per acetyl-CoA oxidized (24 ATP per glucose, since 1 glucose gives 2 acetyl-CoA).

If using glycerol-3-phosphate shuttle (in some tissues), ATP yield slightly less.

⚙️ Regulation of the TCA Cycle

The cycle is regulated mainly at irreversible steps:

1. Citrate synthase

   • Inhibited by ATP, NADH, succinyl-CoA, citrate.

2. Isocitrate dehydrogenase

   • Activated by ADP, Ca²⁺; inhibited by ATP, NADH.

3. α-Ketoglutarate dehydrogenase

   • Activated by Ca²⁺; inhibited by ATP, GTP, NADH, succinyl-CoA.

Additional regulatory aspects:

• Availability of oxaloacetate and acetyl-CoA.

• Energy charge of the cell (ATP/ADP ratio).

• NADH/NAD⁺ ratio (high NADH slows cycle).

• During exercise, ↑ Ca²⁺ in muscle stimulates isocitrate dehydrogenase and α-ketoglutarate dehydrogenase.

                                                                          ? Applied Clinical Aspects

1. Thiamine (B₁) Deficiency

• Impairs α-ketoglutarate dehydrogenase and PDH activity.

• Leads to accumulation of α-ketoglutarate and pyruvate, causing lactic acidosis.

• Clinical syndromes: Beriberi, Wernicke–Korsakoff syndrome.

2. Arsenic and Mercury Poisoning

• Bind to lipoic acid, inhibiting α-ketoglutarate dehydrogenase and PDH.

• Symptoms: Neurologic deficits, GI distress, cardiovascular collapse.

3. Fluoroacetate Poisoning

• Forms fluorocitrate in vivo → inhibits aconitase → blocks citrate → cycle arrest.

• Seen in certain plant toxins and rodenticides.

4. Malonate Inhibition

• Competitive inhibitor of succinate dehydrogenase; experimental tool to study the cycle.

5. Mitochondrial Disorders

• Defects in enzymes of the cycle or ETC reduce ATP yield.

• Clinical picture: Muscle weakness, neurodegeneration, lactic acidosis.

6. Cancer Metabolism

• Some tumor cells use altered TCA cycle intermediates for biosynthesis (oncometabolites such as 2-hydroxyglutarate from mutant isocitrate dehydrogenase).

7. Fumarase Deficiency

• Rare, causes severe neurologic impairment and developmental delay due to impaired energy production.
  

                                                                         ? High-Yield Summary Points

• TCA cycle is amphibolic — integrates catabolism and anabolism.

• Produces NADH, FADH₂, and GTP per acetyl-CoA.

• Three irreversible enzymes are key regulatory points.

• Regulation mainly depends on energy status (ATP/ADP) and NADH/NAD⁺ ratio.

• Several toxins and vitamin deficiencies can halt the cycle and cause energy crisis.

? Introduction

The Electron Transport Chain (ETC) is the final stage of aerobic respiration. It is located in the inner mitochondrial membrane and functions to transfer high-energy electrons from NADH and FADH₂ to molecular oxygen (O₂), forming water.

The energy released during electron transfer is used to pump protons (H⁺) across the inner membrane, creating a proton gradient. This gradient drives ATP synthesis via oxidative phosphorylation.

                                                                      ? Structural Components of ETC

The ETC consists of four multi-subunit protein complexes (I–IV) and two mobile electron carriers (Coenzyme Q / ubiquinone and cytochrome c).

Complex I — NADH: Ubiquinone Oxidoreductase (NADH Dehydrogenase)

• Function: Transfers electrons from NADH to Coenzyme Q (ubiquinone).

• Prosthetic group: FMN (flavin mononucleotide) and Fe-S clusters.

• Proton pumping: Yes — 4 H⁺ pumped into intermembrane space.

• Inhibitor: Rotenone, amobarbital, piericidin A.

• Flow: NADH → FMN → Fe-S → CoQ.

Complex II — Succinate: Ubiquinone Oxidoreductase (Succinate Dehydrogenase)

• Function: Transfers electrons from succinate (via FADH₂) to CoQ.

• Prosthetic group: FAD and Fe-S clusters.

• Proton pumping: No — does not contribute directly to proton gradient.

• Inhibitor: Thenoyltrifluoroacetone, carboxin.

• Special note: Also part of the TCA cycle (Step 6: Succinate → Fumarate).

Coenzyme Q (Ubiquinone)

• Lipid-soluble mobile carrier in the inner membrane.

• Accepts electrons from Complex I and II, transfers them to Complex III.

• Can carry 1 or 2 electrons at a time.

Complex III — Cytochrome bc₁ Complex (Ubiquinol: Cytochrome c Oxidoreductase)

• Function: Transfers electrons from reduced CoQ (ubiquinol) to cytochrome c.

• Prosthetic group: Cytochromes b and c₁, Fe-S protein.

• Proton pumping: Yes — 4 H⁺ pumped into intermembrane space.

• Inhibitor: Antimycin A.

Cytochrome c

• Small, water-soluble heme protein in the intermembrane space.

• Carries 1 electron at a time from Complex III to Complex IV.

Complex IV — Cytochrome c Oxidase

• Function: Transfers electrons from cytochrome c to oxygen, reducing O₂ to water.

• Prosthetic group: Cytochromes a and a₃, Cu²⁺ centers.

• Proton pumping: Yes — 2 H⁺ pumped into intermembrane space.

• Inhibitors: Cyanide, carbon monoxide (CO), sodium azide, hydrogen sulfide (H₂S).

⚙️ Proton Gradient and Chemiosmotic Coupling

• Protons are pumped from the mitochondrial matrix to the intermembrane space, creating:

  • Electrical gradient (positive outside, negative inside).

  • Chemical gradient (low H⁺ inside, high H⁺ outside).

• This proton motive force drives protons back through ATP synthase (Complex V).

• ATP synthase uses the energy to convert ADP + Pᵢ → ATP.

? ATP Yield from ETC (Aerobic Conditions)

• NADH: Passes electrons through Complex I → pumps 10 H⁺ → yields ~2.5 ATP.

• FADH₂: Passes electrons through Complex II → pumps 6 H⁺ → yields ~1.5 ATP.
  

                                                         ? Inhibitors of the Electron Transport Chain

Complex I inhibitors

• Rotenone (insecticide)

• Amobarbital (barbiturate)

• Piericidin A (antibiotic)

• Effect: Blocks NADH electron entry; FADH₂ electrons from Complex II can still generate ATP.

Complex II inhibitors

• Thenoyltrifluoroacetone

• Carboxin

• Effect: Blocks succinate oxidation; NADH pathway remains functional.

Complex III inhibitors

• Antimycin A

• Effect: Blocks electron transfer from CoQ to cytochrome c; halts entire chain.

Complex IV inhibitors

• Cyanide (CN⁻), Carbon monoxide (CO), Sodium azide (NaN₃), Hydrogen sulfide (H₂S)

• Effect: Prevents O₂ from being reduced; electron backup; complete halt of ATP production; rapid cell death.

                                                          ? Uncouplers of Oxidative Phosphorylation

Uncouplers dissipate the proton gradient without inhibiting electron flow. Energy is released as heat instead of ATP synthesis.

Mechanism: Increase permeability of inner mitochondrial membrane to protons → proton motive force collapses → ATP synthase inactive → metabolism speeds up to compensate → heat generation.

Examples:

• 2,4-Dinitrophenol (DNP) — formerly used for weight loss; highly dangerous.

• FCCP (carbonyl cyanide-p-trifluoromethoxyphenylhydrazone) — experimental.

• Thermogenin (UCP1) — physiological uncoupler in brown adipose tissue for non-shivering thermogenesis.

• High-dose salicylates (aspirin overdose) — uncouple mitochondria → hyperthermia, metabolic acidosis.

? Clinical Correlations

1. Cyanide Poisoning

• Source: Industrial exposure, smoke inhalation.

• Inhibits Complex IV → no ATP production → rapid tissue hypoxia despite normal O₂ levels.

• Treatment: Nitrites (induce methemoglobinemia to bind cyanide), thiosulfate (converts CN⁻ to thiocyanate for excretion), hydroxocobalamin.

2. CO Poisoning

• Binds to cytochrome a₃ in Complex IV and to hemoglobin → combined effect of blocking O₂ transport and utilization.

3. Leigh Syndrome

• Rare genetic defect in ETC enzymes or ATP synthase → progressive neurodegeneration, lactic acidosis.

4. Mitochondrial Myopathies

• Defects in mitochondrial DNA encoding ETC proteins → exercise intolerance, muscle weakness.

5. Brown Fat Thermogenesis

• In newborns and hibernating animals, thermogenin uncouples ETC to produce heat instead of ATP, maintaining body temperature.
  

                                                                ? High-Yield Points for Exams

• ETC is in inner mitochondrial membrane; proton pumping occurs at Complexes I, III, IV.

• NADH enters at Complex I; FADH₂ enters at Complex II (yields less ATP).

• ATP synthase inhibition (e.g., oligomycin) stops ATP production but not electron transport until proton gradient is maximized.

• Inhibitors block electron flow; uncouplers collapse proton gradient without blocking electron flow.

• Cyanide, CO → block Complex IV; Antimycin A → blocks Complex III; Rotenone → blocks Complex I.

? Introduction to Bioenergetics

Bioenergetics is the branch of biochemistry that studies how cells capture, store, and use energy to perform work — including biosynthesis, active transport, muscle contraction, and signal transduction.

It focuses on:

• Energy transformations in biological systems.

• Thermodynamic principles governing biochemical reactions.

• The role of high-energy compounds like ATP.

• How catabolic pathways generate energy and anabolic pathways consume it.
  

                                                            ? Fundamental Principles of Bioenergetics

1. The First Law of Thermodynamics — Conservation of Energy

Energy cannot be created or destroyed; it can only change form.
In cells: Chemical energy in glucose → ATP → mechanical work, heat, or other forms.

2. The Second Law of Thermodynamics — Entropy Increase

Every energy transfer increases the disorder (entropy) of the universe.
Biological systems maintain order locally by coupling energy-releasing (exergonic) reactions to energy-requiring (endergonic) reactions.

3. Free Energy (ΔG)

• Definition: The energy available to do work at constant temperature and pressure.

• ΔG < 0 → Exergonic (spontaneous) reaction.

• ΔG > 0 → Endergonic (requires energy input).

• ΔG = 0 → Equilibrium.

Relationship:
ΔG = ΔH – TΔS

• ΔH: change in enthalpy (heat content)

• T: temperature (Kelvin)

• ΔS: change in entropy

4. Standard Free Energy Change (ΔG°')

• Measured under standard conditions: 1 M reactants/products, 25°C, pH 7.0.

• Actual ΔG in cells depends on substrate/product concentrations — even an unfavorable ΔG°' can be driven forward in vivo if product concentration is kept low.

⚡ ATP — The Energy Currency of the Cell

Structure

ATP = Adenine + Ribose + Three phosphate groups.
High-energy bonds: The two terminal phosphoanhydride bonds release large amounts of energy upon hydrolysis.

Hydrolysis Reaction

ATP + H₂O → ADP + Pᵢ (ΔG°' ≈ –7.3 kcal/mol)
ATP + H₂O → AMP + PPᵢ (ΔG°' ≈ –10.9 kcal/mol)

Why so much energy?

• Electrostatic repulsion between negatively charged phosphate groups.

• Resonance stabilization of inorganic phosphate.

• Better hydration of hydrolysis products.

ATP Cycle

• ATP formation: From ADP + Pᵢ using energy from catabolism (glycolysis, oxidative phosphorylation, TCA cycle, fatty acid oxidation).

• ATP utilization: For anabolic reactions, active transport, muscle contraction, nerve conduction.

? Coupled Reactions in Bioenergetics

Biological systems couple an endergonic reaction to an exergonic reaction so the net ΔG is negative.
Example:
Glucose + Pᵢ → Glucose-6-phosphate (endergonic)
ATP → ADP + Pᵢ (exergonic)
Coupled via hexokinase → overall reaction is exergonic.

? High-Energy Compounds Beyond ATP

• GTP: Protein synthesis, gluconeogenesis.

• UTP: Glycogen synthesis.

• CTP: Lipid metabolism.

• Creatine phosphate: Energy reservoir in muscle (creatine kinase reaction).

• 1,3-Bisphosphoglycerate, Phosphoenolpyruvate (PEP), Acetyl-CoA: Intermediates with high phosphoryl transfer potential.

? Biological Oxidation and Energy Capture

Energy in nutrients is released by oxidation and captured as ATP.
Three main types:

1. Oxidases: Transfer electrons to oxygen.

2. Dehydrogenases: Transfer electrons to NAD⁺ or FAD.

3. Hydroperoxidases: Use hydrogen peroxide.

Electron carriers in mitochondria: NADH, FADH₂, CoQ, cytochromes.

? Oxidative Phosphorylation — Chemiosmotic Theory

Protons are pumped from the mitochondrial matrix to the intermembrane space during electron transport.
The proton motive force drives protons back through ATP synthase, producing ATP.

ATP yield:

• NADH → ~2.5 ATP

• FADH₂ → ~1.5 ATP

? Clinical Correlations in Bioenergetics

1. Mitochondrial Disorders

• Mutations in mtDNA → defective oxidative phosphorylation.

• Symptoms: Muscle weakness, neurological deficits, lactic acidosis.

2. Hypoxia/Ischemia

• Lack of oxygen → ETC halts → ATP depletion → Na⁺/K⁺ pump failure → cell swelling and death.

3. Inhibitors of Energy Metabolism

• Cyanide, CO → inhibit Complex IV of ETC.

• Oligomycin → inhibits ATP synthase.

• Uncouplers (DNP, thermogenin) → collapse proton gradient, generating heat instead of ATP.

4. Creatine Kinase in Myocardial Infarction

• CK-MB isoenzyme rises in blood after cardiac muscle damage — reflects breakdown of phosphocreatine system.

? High-Yield Summary Points

• Bioenergetics is the application of thermodynamics to biological energy transformations.

• ATP is the universal energy currency; turnover rate is extremely high in active tissues.

• Negative ΔG means spontaneous; positive ΔG requires energy coupling.

• Oxidative phosphorylation couples electron transfer to ATP synthesis via proton gradient.

• Inhibitors block electron flow; uncouplers allow electron flow but dissipate gradient as heat.

? Introduction

Gluconeogenesis is the anabolic pathway in which glucose is synthesized from non-carbohydrate precursors.
It is essentially the reverse of glycolysis but not a simple reversal, because the irreversible steps of glycolysis are bypassed by specific enzymes.

Location:

• Main site: Liver (major contributor to blood glucose homeostasis)

• Secondary site: Renal cortex (especially during prolonged fasting)

• Cellular site: Cytosol, mitochondria, and partly in the endoplasmic reticulum.

Physiological role: Maintains blood glucose during fasting, starvation, prolonged exercise, or low-carbohydrate diet.

                                                         ? Major Precursors of Gluconeogenesis

1. Lactate

   • From anaerobic glycolysis in RBCs and exercising muscle.

   • Converted to pyruvate by lactate dehydrogenase (Cori cycle).

2. Glycerol

   • From hydrolysis of triglycerides in adipose tissue.

   • Converted to dihydroxyacetone phosphate (DHAP) via glycerol kinase and glycerol-3-phosphate dehydrogenase.

3. Glucogenic Amino Acids (mainly alanine)

   • From muscle protein breakdown.

   • Converted to pyruvate or TCA intermediates (Alanine → pyruvate via alanine aminotransferase, glucose-alanine cycle).

4. Propionyl-CoA

   • From odd-chain fatty acid oxidation.

   • Converted to succinyl-CoA → malate → oxaloacetate.

Note: Fatty acids with even-numbered chains cannot be converted to glucose because acetyl-CoA cannot be converted back to pyruvate in humans.

? Overall Reaction of Gluconeogenesis

2 Pyruvate + 4 ATP + 2 GTP + 2 NADH + 6 H₂O → Glucose + 4 ADP + 2 GDP + 6 Pᵢ + 2 NAD⁺ + 2 H⁺

Energy requirement: 6 high-energy phosphate bonds per glucose.

                                ? Step-by-Step Reactions (Bypassing Glycolysis Irreversible Steps)

Step 1: Pyruvate → Oxaloacetate

• Enzyme: Pyruvate carboxylase (mitochondrial).

• Cofactor: Biotin (vitamin B₇) — CO₂ carrier.

• Activator: Acetyl-CoA (signals fat oxidation and low glycolysis).

• Occurs in mitochondria; requires ATP.

Step 2: Oxaloacetate → Phosphoenolpyruvate (PEP)

• Enzyme: PEP carboxykinase (PEPCK).

• Cofactor: GTP as energy source.

• In cytosol (mainly), but mitochondrial isoform also exists.

• Converts OAA to PEP with release of CO₂.

Shuttle note: OAA cannot cross the mitochondrial membrane directly; converted to malate or aspartate, transported to cytosol, then reconverted to OAA.

Step 3: Fructose-1,6-bisphosphate → Fructose-6-phosphate

• Enzyme: Fructose-1,6-bisphosphatase.

• Regulation:

  • Activated by ATP and citrate.

  • Inhibited by AMP and fructose-2,6-bisphosphate.

• Key regulatory step of gluconeogenesis.

Step 4: Glucose-6-phosphate → Glucose

• Enzyme: Glucose-6-phosphatase.

• Present only in liver, kidney, and intestinal mucosa — absent in muscle (therefore muscle glycogen cannot contribute to blood glucose).

• Located in endoplasmic reticulum; hydrolyzes G6P to free glucose for release into blood.
  

                                                                            ⚙️ Regulation of Gluconeogenesis

Reciprocal regulation with glycolysis ensures both pathways are not active simultaneously in the same cell.

1. Allosteric Regulation

   • Pyruvate carboxylase: Activated by acetyl-CoA.

   • Fructose-1,6-bisphosphatase: Activated by ATP, citrate; inhibited by AMP, fructose-2,6-bisphosphate.

2. Hormonal Regulation

   • Glucagon: Stimulates gluconeogenesis by increasing PEPCK transcription and decreasing PFK-2 activity (lowers fructose-2,6-bisphosphate).

   • Insulin: Inhibits gluconeogenesis by increasing PFK-2 activity (raises fructose-2,6-bisphosphate, stimulating glycolysis).

3. Substrate Availability

   • Increased lactate, glycerol, and alanine during fasting/exercise promote gluconeogenesis.

? Integration with Other Pathways

• Cori Cycle: Lactate from muscle/RBC → liver → glucose.

• Glucose-Alanine Cycle: Alanine from muscle → liver → glucose.

• Glycerol Pathway: Glycerol from adipose → DHAP → glucose.
  

                                                                         ? Clinical Aspects

Biotin Deficiency

• Impairs pyruvate carboxylase → inability to start gluconeogenesis → hypoglycemia, lactic acidosis.

• Causes: Raw egg white consumption (avidin binds biotin), prolonged antibiotics.

Fructose-1,6-bisphosphatase Deficiency

• Presents with severe hypoglycemia, lactic acidosis, ketosis after fasting.

• Management: Avoid fasting, give frequent carbohydrate feeds.

Von Gierke Disease (Glycogen Storage Disease type I)

• Deficiency of glucose-6-phosphatase → impaired glycogenolysis and gluconeogenesis → fasting hypoglycemia, lactic acidosis, hepatomegaly.

Alcohol-induced Hypoglycemia

• Ethanol metabolism increases NADH/NAD⁺ ratio, shunting pyruvate to lactate and OAA to malate → gluconeogenesis inhibited → severe hypoglycemia during fasting in alcoholics.
  

                                                               ? High-Yield Summary Points

• Gluconeogenesis occurs mainly in liver (also kidney during prolonged fasting).

• Not simply reverse of glycolysis — has four unique enzymes: Pyruvate carboxylase, PEPCK, Fructose-1,6-bisphosphatase, Glucose-6-phosphatase.

• Energy-intensive process — requires 4 ATP, 2 GTP, and 2 NADH per glucose molecule.

• Regulated reciprocally with glycolysis to avoid futile cycles.

• Defects lead to fasting hypoglycemia and lactic acidosis.

? Key Concept

Gluconeogenesis is not a simple reversal of glycolysis — it bypasses the three irreversible glycolytic steps (catalyzed by hexokinase/glucokinase, PFK-1, and pyruvate kinase) with four unique enzymes. These are the important steps you must remember.

1. Pyruvate → Oxaloacetate

• Enzyme: Pyruvate carboxylase (in mitochondria)

• Cofactor: Biotin (vitamin B₇) — carries activated CO₂

• Energy: Consumes 1 ATP per pyruvate

• Activator: Acetyl-CoA (signals active fat oxidation and low glycolysis)

• Purpose: Adds CO₂ to pyruvate to form oxaloacetate, the first committed step in gluconeogenesis.

2. Oxaloacetate → Phosphoenolpyruvate (PEP)

• Enzyme: PEP carboxykinase (PEPCK)

• Cofactor: GTP

• Location: Cytosol (mainly), mitochondrial isoform also present

• Purpose: Decarboxylates and phosphorylates oxaloacetate to form PEP, enabling reversal of pyruvate kinase step in glycolysis.

3. Fructose-1,6-bisphosphate → Fructose-6-phosphate

• Enzyme: Fructose-1,6-bisphosphatase

• Regulation:

  • Activated by ATP and citrate

  • Inhibited by AMP and fructose-2,6-bisphosphate

• Purpose: Removes a phosphate group without ATP production — reverses PFK-1 step in glycolysis.

4. Glucose-6-phosphate → Glucose

• Enzyme: Glucose-6-phosphatase

• Location: Endoplasmic reticulum of liver and kidney cells (absent in muscle)

• Purpose: Releases free glucose into the blood — final step of gluconeogenesis.

? High-Yield Memory Tip

• First two steps (pyruvate → PEP) bypass pyruvate kinase.

• Third step (F1,6BP → F6P) bypasses PFK-1.

• Fourth step (G6P → glucose) bypasses hexokinase/glucokinase.

? Introduction

Gluconeogenesis is a highly energy-consuming pathway — producing glucose from non-carbohydrate precursors.
Since it runs opposite to glycolysis, both cannot be active in the same cell at the same time — this would cause a futile cycle (waste of ATP without work).
Regulation ensures that gluconeogenesis is active in fasting/starvation and glycolysis is active in the fed state.

                                                                                 
                                                                                    ⚙️ Levels of Regulation

1. Allosteric Regulation (Immediate, Local Control)

a) Pyruvate Carboxylase

• Activator: Acetyl-CoA

  • High acetyl-CoA = active fat oxidation → signals plenty of energy, switch to glucose production.

• Inhibitor: ADP (low energy state — cell needs glycolysis, not gluconeogenesis).

b) PEP Carboxykinase (PEPCK)

• Main control is transcriptional (see hormonal regulation below).

• Inhibited by ADP (low energy).

c) Fructose-1,6-bisphosphatase (F1,6BPase)

• Activator: ATP, citrate (signals abundant energy and TCA intermediates — time to store as glucose).

• Inhibitors:

  • AMP (low energy → activate glycolysis instead)

  • Fructose-2,6-bisphosphate (most potent inhibitor; strongly shifts metabolism toward glycolysis).

d) Glucose-6-phosphatase

• Controlled mainly by substrate availability (G6P level) and hormonal regulation.

2. Hormonal Regulation (Whole-Body Control)

Glucagon (fasting state)

• ↑ Glucagon → ↑ cAMP → activates protein kinase A (PKA).

• PKA phosphorylates PFK-2/FBPase-2 bifunctional enzyme → FBPase-2 active → ↓ Fructose-2,6-bisphosphate.

• Low F2,6BP → inhibits PFK-1 (glycolysis) and activates F1,6BPase (gluconeogenesis).

• Increases transcription of PEPCK gene → enhances gluconeogenic capacity.

Insulin (fed state)

• ↓ cAMP → PKA inactive → PFK-2 active → ↑ F2,6BP.

• High F2,6BP → activates PFK-1 (glycolysis) and inhibits F1,6BPase (gluconeogenesis suppressed).

• Suppresses transcription of PEPCK.

Cortisol (prolonged fasting/stress)

• ↑ Transcription of PEPCK and other gluconeogenic enzymes → increases hepatic glucose output.

3. Substrate Availability

• High lactate, alanine, and glycerol (from exercise, protein breakdown, lipolysis) favor gluconeogenesis.

• Low substrate levels limit gluconeogenic rate.

4. Energy Status (ATP/AMP Ratio)

• High ATP favors gluconeogenesis (energy available to drive synthesis).

• High AMP inhibits gluconeogenesis, favoring glycolysis.

? Reciprocal Regulation with Glycolysis

• Fructose-2,6-bisphosphate is the central “switch” — stimulates glycolysis and inhibits gluconeogenesis.

• Pyruvate kinase in the liver is inactivated by phosphorylation (fasting), preventing PEP from being converted to pyruvate — PEP is instead available for gluconeogenesis.
  

                                                                              ? Clinical Correlations

Alcohol-induced hypoglycemia

• Ethanol metabolism increases NADH/NAD⁺ ratio in liver.

• Drives pyruvate → lactate and OAA → malate, depleting gluconeogenic substrates.

• Can cause severe hypoglycemia after prolonged fasting in alcoholics.

Fructose-1,6-bisphosphatase deficiency

• Inability to bypass PFK-1 step → fasting hypoglycemia, lactic acidosis.

Von Gierke’s disease (G6Pase deficiency)

• Impaired final step → glucose trapped in liver → severe fasting hypoglycemia.
  
  

? High-Yield Memory Hooks

• Acetyl-CoA activates pyruvate carboxylase (start of gluconeogenesis).

• Fructose-2,6-bisphosphate is the main inhibitor of gluconeogenesis.

• Glucagon = glucose gone → increases gluconeogenesis.

• Insulin = glucose in → inhibits gluconeogenesis.

? Introduction

Gluconeogenesis is an anabolic pathway that synthesizes glucose from non-carbohydrate precursors such as lactate, glycerol, and glucogenic amino acids.
It is energy-consuming — because we are building a high-energy molecule (glucose) from smaller, lower-energy molecules.

This energy comes from ATP, GTP, and NADH generated by fat oxidation and other catabolic processes during fasting.

⚡ Overall Stoichiometry (Starting from Pyruvate)

2 Pyruvate + 4 ATP + 2 GTP + 2 NADH + 6 H₂O → Glucose + 4 ADP + 2 GDP + 6 Pᵢ + 2 NAD⁺ + 2 H⁺

Net requirement per molecule of glucose:

• ATP: 4 molecules

• GTP: 2 molecules

• NADH: 2 molecules

• Total high-energy phosphate bonds: 6
  

                                                                            ? Step-by-Step Energy Usage

1. Pyruvate → Oxaloacetate

• Enzyme: Pyruvate carboxylase (mitochondria)

• Energy: 1 ATP per pyruvate (2 ATP per glucose)

• Biotin-dependent; activated by acetyl-CoA.

2. Oxaloacetate → Phosphoenolpyruvate (PEP)

• Enzyme: PEP carboxykinase (cytosol/mitochondria)

• Energy: 1 GTP per pyruvate (2 GTP per glucose).

3. 3-Phosphoglycerate → 1,3-Bisphosphoglycerate

• Enzyme: Phosphoglycerate kinase

• Energy: 1 ATP per molecule (2 ATP per glucose).

4. NADH Requirement

• Step: 1,3-Bisphosphoglycerate → Glyceraldehyde-3-phosphate (reverse of glycolytic step)

• Enzyme: Glyceraldehyde-3-phosphate dehydrogenase

• Energy: Consumes 1 NADH per molecule (2 NADH per glucose).

• NADH for gluconeogenesis in fasting comes mainly from β-oxidation of fatty acids.
  

                                                                             ⚙️ Energy Summary

For 1 molecule of glucose synthesized from 2 molecules of pyruvate:

• 4 ATP (2 at pyruvate carboxylase step, 2 at phosphoglycerate kinase step)

• 2 GTP (PEPCK step)

• 2 NADH (G3P dehydrogenase step)

• Total high-energy bonds = 6 (equivalent to ~18 ATP if NADH oxidation is included).

? Why So Energy Costly?

• Prevents futile cycling with glycolysis.

• Ensures gluconeogenesis runs only when there is ample energy — typically provided by fat oxidation in fasting/starvation.

• Forces the liver to burn fat while making glucose for the brain and RBCs.
  

                                                                                  ? Clinical Correlation

1. Impaired Fat Oxidation

• Without β-oxidation (e.g., medium-chain acyl-CoA dehydrogenase deficiency), ATP and NADH supply falls → gluconeogenesis fails → fasting hypoglycemia.

2. Alcohol-induced Hypoglycemia

• Excess NADH from ethanol metabolism shifts pyruvate to lactate and OAA to malate → depletes gluconeogenic intermediates and halts glucose production.

? High-Yield Exam Points

• Total high-energy cost = 6 high-energy phosphate bonds per glucose.

• NADH requirement links gluconeogenesis to fat oxidation in fasting.

• Pathway is thermodynamically irreversible in vivo due to bypass enzymes and energy investment.

                                                                                             ? Introduction

Glycogen is the storage form of glucose in animals — a highly branched polymer of α-D-glucose linked mainly by α(1→4) glycosidic bonds with branch points via α(1→6) bonds every 8–12 residues.

• Liver glycogen: Maintains blood glucose during fasting.

• Muscle glycogen: Supplies energy for muscle contraction during exercise.

Glycogen metabolism involves two opposing processes:

• Glycogenesis: Synthesis of glycogen from glucose.

• Glycogenolysis: Breakdown of glycogen to glucose-1-phosphate or free glucose.

Both occur in the cytosol and are regulated reciprocally.

                                                                  ? Glycogen Synthesis (Glycogenesis)

1. Glucose → Glucose-6-phosphate (G6P)

• Enzyme: Hexokinase (muscle) or Glucokinase (liver).

• ATP consumed: 1 ATP per glucose.

2. G6P → Glucose-1-phosphate (G1P)

• Enzyme: Phosphoglucomutase.

• Involves a G1,6-bisphosphate intermediate.

3. G1P + UTP → UDP-glucose

• Enzyme: UDP-glucose pyrophosphorylase.

• Energy source: UTP; pyrophosphate (PPi) hydrolysis drives the reaction.

4. UDP-glucose → Glycogen primer elongation

• Enzyme: Glycogen synthase — catalyzes addition of glucose units via α(1→4) bonds to an existing chain.

• Requires a primer — either glycogen fragment or glycogenin (self-glucosylating protein that initiates glycogen synthesis).

5. Branch formation

• Enzyme: Branching enzyme (amylo-α(1→4) → α(1→6) transglycosylase).

• Transfers a block of 6–8 glucose residues from a growing chain to create an α(1→6) linkage.

• Branching increases solubility and number of non-reducing ends for rapid synthesis and degradation.

Regulation of Glycogenesis

• Allosteric:

  • Liver: G6P activates glycogen synthase.

  • Muscle: G6P activates glycogen synthase.

• Hormonal:

  • Insulin → activates glycogen synthase via dephosphorylation (protein phosphatase-1).

  • Glucagon/epinephrine → inactivate glycogen synthase via phosphorylation (PKA).

                                                           ? Glycogen Degradation (Glycogenolysis)

1. Glycogen → Glucose-1-phosphate

• Enzyme: Glycogen phosphorylase.

• Cleaves α(1→4) bonds from non-reducing ends, releasing G1P.

• Requires pyridoxal phosphate (vitamin B₆) as coenzyme.

2. Debranching (two steps)

• Transferase activity: Moves a block of 3 glucose residues from branch to a nearby chain.

• α(1→6) glucosidase activity: Hydrolyzes the α(1→6) bond to release free glucose.

• Both activities are part of the debranching enzyme.

3. G1P → G6P

• Enzyme: Phosphoglucomutase.

4. G6P fate:

• Liver: G6P → Glucose via glucose-6-phosphatase → released into blood.

• Muscle: Lacks glucose-6-phosphatase; G6P enters glycolysis to produce ATP locally.

                                                                                            ? Introduction

Glycogen metabolism consists of:

• Glycogenesis (glycogen synthesis) — anabolic, energy-storing pathway.

• Glycogenolysis (glycogen breakdown) — catabolic, energy-releasing pathway.

Regulation goal: These two opposing pathways must not be active at the same time in the same tissue.
Control is achieved via:

1. Allosteric regulation — rapid, local, energy-status based.

2. Covalent modification (phosphorylation/dephosphorylation) — hormonal control.

3. Hormone-driven changes in enzyme activity — systemic regulation via insulin, glucagon, epinephrine.

⚙️ Key Enzymes

• Glycogen synthase — adds glucose units to glycogen chain.

• Glycogen phosphorylase — removes glucose units as glucose-1-phosphate.

These two enzymes are the main regulatory targets.
Their activity is controlled by reversible phosphorylation and allosteric effectors.

                                                  ? Allosteric Regulation (Immediate, Local Control)

In Liver

• Glycogen synthase: Activated by glucose-6-phosphate (signals abundant glucose).

• Glycogen phosphorylase: Inhibited by glucose-6-phosphate, ATP, and free glucose (signals no need for glycogen breakdown).

In Muscle

• Glycogen synthase: Activated by glucose-6-phosphate.

• Glycogen phosphorylase:

  • Activated by AMP (signals low energy during exercise).

  • Activated by Ca²⁺ (during muscle contraction — Ca²⁺ binds calmodulin in phosphorylase kinase).

  • Inhibited by ATP and glucose-6-phosphate.
    

                                                       ? Covalent Modification — Phosphorylation Control

General rule:

• Phosphorylation → activates glycogen phosphorylase (breakdown) & inactivates glycogen synthase.

• Dephosphorylation → inactivates glycogen phosphorylase & activates glycogen synthase.

Mechanism:

• Hormones regulate phosphorylase kinase (which phosphorylates phosphorylase) and protein phosphatase-1 (which removes phosphate groups).

                                                                  ? Hormonal Regulation (Systemic Control)

Fed State — Insulin Dominance

• Signal: High blood glucose after a meal.

• Mechanism:

  1. Insulin binds to its receptor → activates protein phosphatase-1.

  2. Protein phosphatase-1 dephosphorylates glycogen synthase (activating it) and glycogen phosphorylase (inactivating it).

  3. Net effect: ↑ Glycogen synthesis, ↓ glycogen breakdown.

Fasting State — Glucagon (Liver)

• Signal: Low blood glucose.

• Mechanism:

  1. Glucagon binds to liver GPCR → activates adenylate cyclase → ↑ cAMP → activates protein kinase A (PKA).

  2. PKA phosphorylates and activates phosphorylase kinase → activates glycogen phosphorylase.

  3. PKA also phosphorylates and inactivates glycogen synthase.

  4. Net effect: ↑ Glycogen breakdown to release glucose into blood.

Exercise/Stress — Epinephrine

• In Liver: Works like glucagon (β-adrenergic → cAMP pathway) to break down glycogen for blood glucose.

• In Muscle:

  • β-adrenergic: ↑ cAMP → PKA → phosphorylase kinase → glycogen phosphorylase activation.

  • α-adrenergic: Via IP₃ and Ca²⁺ release → phosphorylase kinase activation.

  • Ca²⁺ from muscle contraction also activates phosphorylase kinase via calmodulin — ensures glycogen breakdown matches muscle activity.

? Reciprocal Regulation Logic

• Same phosphorylation event has opposite effects on the two enzymes:

  • Glycogen synthase → inactivated.

  • Glycogen phosphorylase → activated.

• Prevents futile cycling — ensures only synthesis or breakdown occurs at a given time.

                                                                           ? Clinical Correlations

1. McArdle Disease (Type V GSD)

• Muscle phosphorylase deficiency → inability to mobilize glycogen in muscle → exercise intolerance, myoglobinuria.

2. Von Gierke Disease (Type I GSD)

• Glucose-6-phosphatase deficiency → liver can’t release glucose → severe fasting hypoglycemia despite normal glycogen breakdown.

3. Hers Disease (Type VI GSD)

• Liver phosphorylase deficiency → mild fasting hypoglycemia, hepatomegaly.

4. Excess catecholamine states

• Pheochromocytoma or stress can cause excessive glycogen breakdown → hyperglycemia.
  

                                                                   ? High-Yield Summary Points

• Insulin = “Store” → activates glycogen synthase, inhibits glycogen phosphorylase.

• Glucagon/Epinephrine = “Mobilize” → activate glycogen phosphorylase, inhibit glycogen synthase.

• Muscle glycogenolysis is driven by AMP and Ca²⁺ in exercise, not by glucagon.

• Reciprocal regulation prevents synthesis and breakdown from happening simultaneously.

                                                                                              ? Introduction

Glycogen Storage Disorders (GSDs) are a group of inherited metabolic disorders caused by deficiency of enzymes involved in glycogen synthesis or degradation.
This leads to abnormal quantity or structure of glycogen in tissues, causing symptoms related to the liver, muscle, and sometimes the heart.

Main affected organs:

• Liver → regulates blood glucose via glycogen metabolism.

• Muscle → uses glycogen for energy during contraction.

                                                                                                 ? Classification

GSDs are traditionally numbered (Type I–XIII), based on order of discovery and enzyme defect.
Most important and exam-relevant: Types I–VII.

? Detailed Types

Type I — Von Gierke Disease

• Enzyme deficiency: Glucose-6-phosphatase (liver, kidney, intestine).

• Biochemical effect: Impaired glycogenolysis and gluconeogenesis (final step blocked).

• Pathology: Large amounts of normal-structured glycogen in liver and kidney.

• Clinical features:

  • Severe fasting hypoglycemia.

  • Lactic acidosis (lactate ↑ because pyruvate → lactate).

  • Hyperuricemia (due to increased AMP degradation → uric acid).

  • Hyperlipidemia.

  • Hepatomegaly, renomegaly, growth retardation.

• Treatment: Frequent cornstarch meals, avoid fasting, avoid galactose/fructose (increases G6P load).

Type II — Pompe Disease

• Enzyme deficiency: Lysosomal acid α(1→4) glucosidase (acid maltase).

• Biochemical effect: Impaired degradation of glycogen in lysosomes.

• Pathology: Glycogen accumulates in lysosomes in many tissues, especially muscle.

• Clinical features:

  • Infantile form: Severe hypotonia ("floppy baby"), cardiomegaly, hepatomegaly, respiratory failure, death in infancy.

  • Late-onset form: Progressive skeletal muscle weakness, respiratory issues.

• Key point: Only GSD that is a lysosomal storage disease.

• Treatment: Enzyme replacement therapy.

Type III — Cori Disease (Forbes Disease)

• Enzyme deficiency: Debranching enzyme (amylo-1,6-glucosidase / 4-α-glucanotransferase).

• Biochemical effect: Incomplete glycogenolysis — accumulation of abnormally structured glycogen with short outer branches ("limit dextrins").

• Clinical features:

  • Mild hypoglycemia.

  • Hepatomegaly.

  • Muscle weakness (myopathy in some cases).

• Note: Milder than Type I because gluconeogenesis is intact.

Type IV — Andersen Disease

• Enzyme deficiency: Branching enzyme (amylo-1,4→1,6-transglucosidase).

• Biochemical effect: Production of glycogen with very long, unbranched chains.

• Pathology: Abnormal glycogen precipitates in liver and other tissues → triggers immune-mediated fibrosis and cirrhosis.

• Clinical features:

  • Failure to thrive, hepatosplenomegaly, progressive liver cirrhosis.

  • Death usually by age 5 without liver transplant.

Type V — McArdle Disease

• Enzyme deficiency: Muscle glycogen phosphorylase (myophosphorylase).

• Biochemical effect: Muscle cannot break down glycogen → poor energy supply during exercise.

• Clinical features:

  • Exercise intolerance, muscle cramps, myoglobinuria after exercise.

  • No rise in blood lactate after exercise (anaerobic glycolysis blocked).

• Key point: Blood glucose levels remain normal (liver unaffected).

• Treatment: Avoid intense exercise; consume sucrose before activity for extra fuel.

Type VI — Hers Disease

• Enzyme deficiency: Liver glycogen phosphorylase.

• Biochemical effect: Impaired glycogenolysis in liver.

• Clinical features:

  • Mild fasting hypoglycemia.

  • Hepatomegaly, growth retardation.

  • Generally benign course.

Type VII — Tarui Disease

• Enzyme deficiency: Muscle phosphofructokinase (PFK-1).

• Biochemical effect: Glycolysis blocked in muscle → glycogen utilization impaired.

• Clinical features:

  • Exercise intolerance, muscle cramps, myoglobinuria.

  • Hemolytic anemia (RBC PFK deficiency).

                                                                                 ⚙️ Summary of Patterns

Liver GSDs (Type I, III, IV, VI):

• Hypoglycemia, hepatomegaly.

Muscle GSDs (Type V, VII):

• Exercise intolerance, cramps, myoglobinuria.

General metabolic derangements:

• Energy deficit.

• Abnormal glycogen accumulation or structure.

? Clinical Examination Tips for MBBS/PG Exams

• Type I (Von Gierke): Severe fasting hypoglycemia + lactic acidosis + hepatomegaly = think G6Pase deficiency.

• Type II (Pompe): Cardiomegaly + hypotonia = lysosomal α-glucosidase deficiency.

• Type V (McArdle): Exercise intolerance + myoglobinuria + no lactate rise on exercise.

? Memory Hook — "Very Poor Carbohydrate Metabolism Has Trouble"

V = Von Gierke (I) — Glucose-6-phosphatase
P = Pompe (II) — Lysosomal α-glucosidase
C = Cori (III) — Debranching enzyme
M = McArdle (V) — Muscle phosphorylase
H = Hers (VI) — Liver phosphorylase
T = Tarui (VII) — PFK-1 (muscle)

? Introduction

The Pentose Phosphate Pathway (PPP) — also called the Hexose Monophosphate (HMP) Shunt — is an alternative cytosolic pathway for glucose metabolism that runs parallel to glycolysis.

Main purposes:

1. Generate NADPH — for reductive biosynthesis and antioxidant defense.

2. Produce ribose-5-phosphate — for nucleotide and nucleic acid synthesis.

Unique feature:

• No direct ATP production.

• Operates in all cells, but is most active in tissues requiring high NADPH (e.g., liver, adrenal cortex, mammary glands, RBCs).

? Location

• Cellular site: Cytosol.

• Major organs: Liver, adipose tissue, lactating mammary gland, adrenal cortex, testes, and erythrocytes.

? Functions of PPP

• NADPH production for:

  • Fatty acid synthesis (liver, adipose, mammary).

  • Cholesterol and steroid synthesis (adrenal cortex, gonads).

  • Regeneration of reduced glutathione in RBCs (antioxidant defense).

  • Detoxification reactions via cytochrome P450.

• Ribose-5-phosphate production for:

  • DNA and RNA synthesis.

  • Coenzymes (NAD⁺, FAD, CoA).

? Phases of the Pentose Phosphate Pathway

1. Oxidative Phase (Irreversible)

Purpose: Produce NADPH and ribulose-5-phosphate.

Step 1: Glucose-6-phosphate → 6-phosphoglucono-δ-lactone

• Enzyme: Glucose-6-phosphate dehydrogenase (G6PD).

• Cofactor: NADP⁺ (reduced to NADPH).

• Regulation: Inhibited by NADPH (feedback).

Step 2: 6-phosphoglucono-δ-lactone → 6-phosphogluconate

• Enzyme: Lactonase.

Step 3: 6-phosphogluconate → Ribulose-5-phosphate + CO₂

• Enzyme: 6-phosphogluconate dehydrogenase.

• Cofactor: NADP⁺ → NADPH.

Net products of oxidative phase (per G6P):

• 2 NADPH

• 1 ribulose-5-phosphate

• 1 CO₂

2. Non-Oxidative Phase (Reversible)

Purpose: Interconvert sugars for nucleotide synthesis or return to glycolysis.

• Ribulose-5-phosphate is converted to:

  • Ribose-5-phosphate → nucleotide synthesis.

  • Xylulose-5-phosphate → sugar rearrangements.

Key enzymes:

• Transketolase (requires thiamine pyrophosphate, TPP).

• Transaldolase.

Products:

• Can generate glyceraldehyde-3-phosphate and fructose-6-phosphate to re-enter glycolysis/gluconeogenesis.

• Provides flexibility — if ribose is not needed, carbons are recycled for energy metabolism.

⚙️ Regulation of PPP

• Rate-limiting enzyme: Glucose-6-phosphate dehydrogenase (G6PD).

• Main regulator: NADP⁺ availability (high NADP⁺ stimulates, high NADPH inhibits).

• Insulin upregulates G6PD gene expression — stimulates PPP in fed state for lipid synthesis.

? Clinical Correlation — G6PD Deficiency

Pathophysiology:

• X-linked recessive disorder.

• Decreased G6PD → decreased NADPH → impaired regeneration of reduced glutathione (GSH).

• RBCs vulnerable to oxidative stress → hemolytic anemia.

Triggers:

• Oxidative drugs (primaquine, sulfa drugs, dapsone, nitrofurantoin).

• Fava beans (favism).

• Infections (generate reactive oxygen species).

Peripheral smear:

• Heinz bodies (denatured hemoglobin precipitates).

• Bite cells (splenic macrophages remove Heinz bodies).

Protective effect:

• Confers resistance to Plasmodium falciparum malaria.

? High-Yield Summary Points

• Oxidative phase → irreversible → makes NADPH and ribulose-5-phosphate.

• Non-oxidative phase → reversible → sugar interconversion via transketolase/transaldolase.

• NADPH uses: lipid biosynthesis, antioxidant defense, cytochrome P450 reactions.

• Key regulator: G6PD, activated by NADP⁺, inhibited by NADPH.

• Deficiency: G6PD deficiency → hemolysis under oxidative stress.

? Introduction

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy in humans, affecting ~400 million people worldwide.
It is an X-linked recessive disorder, leading to impaired production of NADPH in the pentose phosphate pathway.

Because red blood cells (RBCs) depend entirely on the pentose phosphate pathway for NADPH production, this deficiency makes them vulnerable to oxidative damage, resulting in episodic hemolytic anemia.

? Enzyme and Pathway Context

• G6PD function: Catalyzes the first (rate-limiting) step of the oxidative phase of the PPP:
  Glucose-6-phosphate + NADP⁺ → 6-phosphoglucono-δ-lactone + NADPH.

• NADPH roles in RBCs:

  • Regenerates reduced glutathione (GSH) from oxidized glutathione (GSSG) via glutathione reductase.

  • GSH detoxifies hydrogen peroxide (H₂O₂) via glutathione peroxidase, preventing oxidative damage to hemoglobin and membranes.

• Without NADPH: Oxidative stress causes hemoglobin denaturation → Heinz bodies → RBC membrane damage → extravascular and intravascular hemolysis.

? Genetics and Epidemiology

• Inheritance: X-linked recessive → mostly males affected; heterozygous females usually asymptomatic but may show mild symptoms due to X-inactivation (Lyonization).

• Prevalence: High in malaria-endemic regions (Africa, Middle East, Mediterranean, Asia).

• Evolutionary advantage: Partial protection against Plasmodium falciparum malaria.

? Pathophysiology

1. Trigger exposure → increased oxidative stress in RBCs.

2. In G6PD-deficient RBCs → insufficient NADPH → glutathione remains oxidized.

3. Accumulation of reactive oxygen species damages:

   • Hemoglobin → precipitates as Heinz bodies.

   • RBC membrane → decreased deformability → splenic macrophages “bite” out damaged parts (bite cells).

4. Damaged RBCs undergo:

   • Extravascular hemolysis in spleen (most common).

   • Intravascular hemolysis in severe oxidative stress.

⚠️ Common Triggers

• Drugs: Antimalarials (primaquine, chloroquine), sulfonamides (sulfamethoxazole), nitrofurantoin, dapsone, isoniazid.

• Foods: Fava beans (Vicia faba) → “favism.”

• Infections: Most common trigger — due to ROS production by activated neutrophils.

• Others: Naphthalene (mothballs).

? Clinical Features

Between Attacks

• Usually asymptomatic; normal hemoglobin and RBC morphology.

During Hemolytic Episode (24–72 hrs after trigger)

• Acute onset of pallor, fatigue, jaundice, scleral icterus.

• Dark urine (hemoglobinuria).

• Mild to severe anemia; tachycardia; splenomegaly possible.

Neonatal jaundice

• May present within first week of life; risk of kernicterus.

? Laboratory Findings

• CBC: Normocytic normochromic anemia during attack.

• Peripheral smear:

  • Heinz bodies (stain with supravital stains like crystal violet).

  • Bite cells (“degmacytes”) due to splenic macrophage removal of Heinz bodies.

• Reticulocytosis: Increased after onset as marrow responds.

• Indirect (unconjugated) bilirubin: Elevated (hemolysis).

• LDH: Increased (cell breakdown).

• Haptoglobin: Decreased (binds free hemoglobin in intravascular hemolysis).

• Enzyme assay: Low G6PD activity — should be done after acute hemolytic episode resolves (during crisis, reticulocytes with normal enzyme may give false normal).

⚙️ WHO Classification (Severity)

• Class I: Severe, chronic non-spherocytic hemolytic anemia (rare).

• Class II: Severe deficiency (<10% activity), intermittent hemolysis (Mediterranean variant).

• Class III: Moderate deficiency (10–60% activity), hemolysis with oxidative stress (African variant).

• Class IV: Normal activity (no clinical disease).

• Class V: Increased activity (no clinical significance).

? Management

Acute episode:

• Remove and avoid the trigger.

• Supportive care: Oxygen, hydration, transfusion if severe anemia.

• Treat underlying infection if present.

Neonatal jaundice:

• Phototherapy.

• Exchange transfusion if bilirubin dangerously high.

Long-term:

• Patient education — avoid oxidative drugs and fava beans.

• Screening in high-prevalence areas.

? High-Yield Exam Points

• Most common human enzyme deficiency.

• X-linked recessive inheritance — mostly symptomatic in males.

• Key diagnostic clue: Bite cells + Heinz bodies after oxidative stress.

• Most common trigger: Infection; most famous trigger: fava beans.

• Peripheral smear is more helpful acutely than enzyme assay (due to reticulocyte interference).

• Provides malaria resistance.

                                                                                    ? Uronic Acid Pathway

Introduction

The uronic acid pathway (also called the glucuronic acid pathway) is an alternate oxidative pathway for glucose metabolism that runs in the cytosol of many tissues, especially the liver.
It does not produce ATP, but it generates UDP-glucuronic acid — an important activated sugar for conjugation reactions and polysaccharide synthesis.

Functions of the Uronic Acid Pathway

1. Formation of UDP-glucuronic acid for:

   • Conjugation of bilirubin (bilirubin diglucuronide in bile).

   • Detoxification of drugs, hormones, and xenobiotics via glucuronidation.

   • Formation of glycosaminoglycans (GAGs) like hyaluronic acid, chondroitin sulfate.

2. Oxidation of glucose to glucuronic acid — important for metabolism of certain substances.

3. Synthesis of L-ascorbic acid (Vitamin C) in animals (except humans, primates, guinea pigs, some birds and fish — due to lack of L-gulonolactone oxidase).

Pathway Steps (Starting from Glucose-6-phosphate)

1. Glucose-6-phosphate → Glucose-1-phosphate

   • Enzyme: Phosphoglucomutase.

2. Glucose-1-phosphate → UDP-glucose

   • Enzyme: UDP-glucose pyrophosphorylase.

3. UDP-glucose → UDP-glucuronic acid

   • Enzyme: UDP-glucose dehydrogenase (requires NAD⁺).

4. UDP-glucuronic acid has two fates:

   • Used in conjugation reactions (bilirubin, drugs, steroids).

   • Converted to L-gulonate → L-xylulose → D-xylulose → enters pentose phosphate pathway.

Special Notes

• In humans, the uronic acid pathway is incomplete for vitamin C synthesis because we lack L-gulonolactone oxidase.

• Pathway overlaps with PPP in metabolism of pentoses.
  

                                                                                   ? Essential Pentosuria

Definition

A rare, benign, autosomal recessive inborn error of metabolism caused by deficiency of L-xylulose reductase in the uronic acid pathway.

Biochemical Defect

• Normally: L-xylulose is reduced to xylitol by L-xylulose reductase.

• In deficiency: L-xylulose accumulates and is excreted in urine.

Clinical Features

• Usually asymptomatic.

• Main finding: High levels of L-xylulose in urine → gives positive Benedict’s test (reducing sugar).

Clinical Importance

• Differential diagnosis: Must be distinguished from glucosuria due to diabetes mellitus.

  • In diabetes → urine contains glucose (reducing sugar) + hyperglycemia.

  • In essential pentosuria → blood glucose is normal; sugar in urine is L-xylulose.

Diagnosis

• Positive Benedict’s test, negative glucose oxidase test.

• Confirmed by chromatography of urine sugars.

Management

• No treatment needed (benign).

• Patient reassurance.

? High-Yield Summary

• Uronic acid pathway produces UDP-glucuronic acid for detoxification, bilirubin conjugation, GAG synthesis.

• Humans cannot synthesize vitamin C because of lack of L-gulonolactone oxidase.

• Essential pentosuria: L-xylulose reductase deficiency → benign pentose excretion in urine → positive Benedict’s test but normal blood sugar.

                                                                                      ? Introduction

Fructose is a monosaccharide (ketohexose) found naturally in fruits, honey, and sucrose (as part of a disaccharide).
It is a dietary sugar and also formed endogenously from glucose via the polyol pathway.

Why important?

• It bypasses the main regulatory step of glycolysis (phosphofructokinase-1, PFK-1).

• Rapid metabolism → unregulated entry into glycolysis → potential for overproduction of lipids and uric acid.
  

                                                                                ? Sources of Fructose

1. Dietary:

   • Free fructose in fruits and honey.

   • Sucrose (glucose + fructose) from sugarcane, sugar beet.

2. Endogenous synthesis (Polyol Pathway):

   • In seminal vesicles: Glucose → sorbitol → fructose.

   • Fructose provides energy to sperm cells in semen.

? Metabolism of Fructose — Liver Pathway

Main site: Liver (also kidney and small intestine mucosa).

Step 1 — Phosphorylation of Fructose

Fructose → Fructose-1-phosphate

• Enzyme: Fructokinase (ketohexokinase)

• Cofactor: ATP → ADP

• High affinity for fructose; not regulated by insulin or feedback inhibition.

Step 2 — Cleavage of Fructose-1-phosphate

Fructose-1-phosphate → Dihydroxyacetone phosphate (DHAP) + Glyceraldehyde

• Enzyme: Aldolase B (liver-specific; also acts on fructose-1,6-bisphosphate in glycolysis).

• Rate-limiting step for hepatic fructose metabolism.

Step 3 — Conversion of Glyceraldehyde

Glyceraldehyde → Glyceraldehyde-3-phosphate (G3P)

• Enzyme: Triose kinase

• Cofactor: ATP

DHAP and G3P enter glycolysis, gluconeogenesis, or lipid synthesis.

? Metabolism of Fructose in Extrahepatic Tissues

• In adipose tissue, muscle, kidney:
  Fructose → Fructose-6-phosphate via hexokinase (low affinity, only when glucose low).

• This enters glycolysis at the PFK-1 step.

                                                                                   ⚙️ Regulation

• Hepatic fructose metabolism is unregulated because it bypasses PFK-1 (main glycolytic control point).

• Entry depends only on fructose availability and enzyme capacity.

? Applied Clinical Aspects

1. Essential Fructosuria

• Enzyme defect: Fructokinase deficiency (benign, autosomal recessive).

• Effect: Fructose not phosphorylated → excreted in urine.

• Clinical features: Asymptomatic; incidental finding of reducing sugar in urine (positive Benedict’s test, negative glucose oxidase test).

• Management: None needed.

2. Hereditary Fructose Intolerance (HFI)

• Enzyme defect: Aldolase B deficiency (autosomal recessive).

• Pathophysiology:

  • Fructose-1-phosphate accumulates in liver, kidney, and small intestine.

  • Sequestration of phosphate → ↓ ATP → inhibits glycogenolysis and gluconeogenesis.

  • Leads to severe hypoglycemia, lactic acidosis, hyperuricemia.

• Clinical presentation:

  • Onset after introduction of fructose, sucrose, or sorbitol in diet (infants after weaning).

  • Vomiting, irritability, sweating, tremors, seizures, jaundice, hepatomegaly.

• Lab findings: Hypoglycemia, hyperuricemia, metabolic acidosis, positive Benedict’s test (reducing sugar in urine).

• Management:

  • Eliminate fructose, sucrose, and sorbitol from diet.

  • Lifelong dietary restriction prevents complications.

3. Fructose and Hyperuricemia

• Excess fructose metabolism rapidly uses ATP → ↑ AMP degradation → uric acid production → hyperuricemia, possible gout.

• Seen in high-fructose diets (soft drinks, processed foods).

4. Role in Male Fertility

• Seminal vesicles produce fructose via the polyol pathway.

• Fructose in semen provides energy for sperm motility.

? High-Yield Summary

• Liver: Fructose → F1P (fructokinase) → DHAP + glyceraldehyde (aldolase B) → glycolysis/lipogenesis.

• Muscle/adipose: Fructose → F6P via hexokinase.

• Essential fructosuria: Fructokinase deficiency — benign.

• HFI: Aldolase B deficiency — severe hypoglycemia after fructose intake; avoid fructose/sucrose/sorbitol.

• Fructose metabolism is rapid and unregulated — bypasses PFK-1.

Galactose is a monosaccharide (aldohexose) primarily obtained from the digestion of lactose, the main sugar in milk.
It is metabolized mainly in the liver, but also in other tissues that use it for glycoprotein and glycolipid synthesis.

? Sources of Galactose

1. Dietary:

   • Lactose (milk sugar) → hydrolyzed by lactase in the intestinal brush border into glucose + galactose.

2. Endogenous:

   • From breakdown of complex carbohydrates (glycoproteins, glycolipids).

? Metabolism of Galactose — Leloir Pathway (Main Pathway)

Step 1 — Phosphorylation of Galactose
Galactose → Galactose-1-phosphate

• Enzyme: Galactokinase

• Cofactor: ATP → ADP

• Purpose: Traps galactose inside the cell.

Step 2 — Exchange with UDP-glucose
Galactose-1-phosphate + UDP-glucose → UDP-galactose + Glucose-1-phosphate

• Enzyme: Galactose-1-phosphate uridyltransferase (GALT)

• Key reaction linking galactose metabolism to glucose metabolism.

• Glucose-1-phosphate → Glucose-6-phosphate → Glycolysis / Glycogenesis.

Step 3 — Conversion of UDP-galactose to UDP-glucose
UDP-galactose → UDP-glucose

• Enzyme: UDP-galactose 4-epimerase

• Allows recycling of UDP-glucose for continued metabolism of galactose.

Special Role of UDP-galactose

• Precursor for:

  • Lactose synthesis in mammary glands (via lactose synthase).

  • Glycoproteins and glycolipids (cell membrane components).

⚙️ Regulation

• Controlled mainly by substrate availability (dietary galactose).

• Indirectly influenced by rate of lactose intake and lactase activity.

? Applied Clinical Aspects

1. Classic Galactosemia

• Enzyme defect: Galactose-1-phosphate uridyltransferase (GALT) deficiency (autosomal recessive).

• Pathophysiology:

  • Accumulation of galactose-1-phosphate in liver, brain, kidney → toxic to tissues.

  • Inhibits hepatic glycogen metabolism and gluconeogenesis → hypoglycemia.

  • Excess galactose → reduced to galactitol by aldose reductase → cataracts.

• Clinical features:

  • Onset in newborns after milk feeding.

  • Jaundice, hepatomegaly, vomiting, poor feeding, hypoglycemia, lethargy.

  • Risk of E. coli sepsis in neonates.

• Complications: Intellectual disability, speech/language deficits, ovarian failure if untreated.

• Treatment: Lifelong elimination of galactose and lactose from diet.

2. Galactokinase Deficiency

• Enzyme defect: Galactokinase (rare, autosomal recessive).

• Pathophysiology:

  • Accumulation of galactose in blood and urine.

  • Galactose → galactitol in lens → cataracts (especially in infancy).

• Clinical features:

  • Early cataracts; otherwise generally mild, no severe systemic disease.

• Treatment: Dietary restriction of galactose.

3. UDP-galactose 4-epimerase Deficiency

• Rare; two forms:

  • Benign form: No major symptoms; found incidentally.

  • Severe form: Similar to classic galactosemia with additional glycoprotein/glycolipid synthesis defects.

4. Cataract Formation in Galactose Disorders

• Mechanism:

  • Aldose reductase reduces galactose → galactitol in lens.

  • Galactitol is osmotically active → water influx → lens fiber damage → opacity.

? High-Yield Summary

• Galactose metabolism (Leloir pathway): Galactose → Gal-1-P (galactokinase) → UDP-galactose (GALT) → UDP-glucose (epimerase).

• Classic galactosemia: GALT deficiency → severe neonatal symptoms, risk of E. coli sepsis, requires lactose-free diet.

• Galactokinase deficiency: Milder, causes cataracts without systemic illness.

• UDP-galactose 4-epimerase deficiency: Rare, may mimic classic galactosemia in severe form.

• Complications are mainly due to galactitol accumulation and Gal-1-P toxicity.

? Introduction

The polyol pathway (also called the sorbitol pathway) is a two-step metabolic route that converts glucose → sorbitol → fructose.

• Normally a minor pathway of glucose metabolism.

• Becomes more active when blood glucose levels are high (e.g., uncontrolled diabetes).

? Steps of the Polyol Pathway

Step 1 — Reduction of Glucose to Sorbitol

Reaction:
Glucose + NADPH + H⁺ → Sorbitol + NADP⁺

• Enzyme: Aldose reductase

• Cofactor: NADPH (provides reducing power).

• Significance:

  • In seminal vesicles, this is the first step in fructose production for sperm energy.

  • In hyperglycemia, excessive glucose is shunted into this pathway.

Step 2 — Oxidation of Sorbitol to Fructose

Reaction:
Sorbitol + NAD⁺ → Fructose + NADH + H⁺

• Enzyme: Sorbitol dehydrogenase

• Cofactor: NAD⁺

• Tissue distribution: Present in liver, ovaries, seminal vesicles — allowing fructose formation.

? Tissue Distribution

Tissues with BOTH enzymes (aldose reductase + sorbitol dehydrogenase) → Can convert glucose to fructose efficiently:

• Liver

• Ovaries

• Seminal vesicles

Tissues with ONLY aldose reductase (no sorbitol dehydrogenase) → Sorbitol accumulates:

• Lens

• Retina

• Schwann cells (peripheral nerves)

• Kidney

• Blood vessels

These tissues are vulnerable in chronic hyperglycemia.

⚙️ Physiological Role

1. Fructose production in seminal vesicles:

   • Sperm cells use fructose as an energy source in semen.

2. Minor alternative glucose metabolism route in normal conditions.

? Pathological Significance — Sorbitol Accumulation

In Hyperglycemia (e.g., uncontrolled Diabetes Mellitus):

• High intracellular glucose in insulin-independent tissues (lens, retina, nerves, kidney) → ↑ aldose reductase activity → sorbitol accumulation.

• If sorbitol dehydrogenase is absent/low, sorbitol builds up → osmotic stress → water influx → cell swelling and damage.

Complications Linked to Sorbitol Accumulation

• Lens: Cataract formation (lens opacity due to osmotic damage + protein precipitation).

• Nerves: Diabetic peripheral neuropathy (Schwann cell damage).

• Retina: Diabetic retinopathy.

• Kidney: Diabetic nephropathy.

? Clinical Correlation: Cataract Formation Mechanism

1. Hyperglycemia → excess glucose enters lens.

2. Aldose reductase converts glucose → sorbitol.

3. Sorbitol cannot exit easily and accumulates.

4. Osmotic stress damages lens fibers; crystallin proteins aggregate → lens opacity.

? High-Yield Summary

• Enzymes: Aldose reductase (glucose → sorbitol), Sorbitol dehydrogenase (sorbitol → fructose).

• Key tissues:

  • With both enzymes → fructose production (liver, ovaries, seminal vesicles).

  • With only aldose reductase → sorbitol accumulation & damage (lens, retina, Schwann cells, kidney).

• Pathology: Chronic hyperglycemia → sorbitol buildup → cataracts, neuropathy, retinopathy, nephropathy.

• Clinical tie-in: Basis for many diabetic microvascular complications.

? Introduction

In the human body, metabolism is not a collection of isolated reactions — it is a network of interconnected pathways.

• Integration allows the body to adapt to different nutritional states, activity levels, and hormonal signals.

• The liver, muscle, adipose tissue, brain, and RBCs each have specialized roles.

• Integration depends mainly on availability of substrates and hormonal control (insulin, glucagon, epinephrine, cortisol).

? Metabolic States

1. Fed (Absorptive) State — up to ~4 hours after a meal

• High insulin : glucagon ratio.

• Purpose: Store excess nutrients and provide immediate fuel for energy needs.

Carbohydrate metabolism:

• Dietary glucose → ↑ blood glucose → stimulates insulin release.

• Liver: ↑ glycogenesis, ↑ glycolysis, ↑ lipogenesis.

• Muscle: ↑ glucose uptake (via GLUT-4), ↑ glycogenesis.

• Adipose tissue: ↑ glucose uptake, ↑ triglyceride synthesis.

Lipid metabolism:

• Liver: Excess acetyl-CoA from glycolysis → fatty acid synthesis → triglycerides.

• Adipose: Stores triglycerides (requires glycerol-3-phosphate from glucose).

Protein metabolism:

• Dietary amino acids used for protein synthesis; excess carbon skeletons → energy or fat synthesis.

2. Fasting (Post-absorptive) State — ~4–16 hours after last meal

• Low insulin : glucagon ratio.

• Purpose: Maintain blood glucose for glucose-dependent tissues (brain, RBCs).

Carbohydrate metabolism:

• Liver: Glycogenolysis is the major source of blood glucose.

• Gluconeogenesis begins (from lactate, glycerol, alanine).

Lipid metabolism:

• Adipose tissue: Lipolysis → free fatty acids (FFA) + glycerol.

• Liver: FFA → β-oxidation → acetyl-CoA → ketone bodies (minimal in early fasting).

Protein metabolism:

• Muscle proteolysis provides alanine for gluconeogenesis.

? Key Integrative Points

1. Glucose as a Central Fuel

• In the fed state, glucose is oxidized for ATP and stored as glycogen or fat.

• In fasting, glucose is preserved for brain and RBCs; other tissues shift to fat.

2. Acetyl-CoA as a Hub

• Produced from carbohydrate (glycolysis → pyruvate → acetyl-CoA), fat (β-oxidation), and some amino acids.

• Cannot be converted back to glucose (pyruvate dehydrogenase reaction is irreversible).

• Used for TCA cycle, ketogenesis, fatty acid synthesis.

3. TCA Cycle as the Meeting Point

• Intermediates link carbohydrate, fat, and amino acid metabolism.

• E.g., oxaloacetate → gluconeogenesis; citrate → fatty acid synthesis.

? Tissue-Specific Roles in Fed and Fasting States (Overview)

Liver:

• Fed: Glycogenesis, glycolysis, lipogenesis, amino acid metabolism.

• Fasting: Glycogenolysis, gluconeogenesis, ketogenesis.

Muscle:

• Fed: Glucose uptake (GLUT-4), glycogen synthesis, protein synthesis.

• Fasting: Uses fatty acids, ketone bodies; provides amino acids for gluconeogenesis.

Adipose:

• Fed: Glucose uptake, triglyceride synthesis.

• Fasting: Lipolysis → fatty acids + glycerol.

Brain:

• Fed: Glucose is sole fuel.

• Fasting (prolonged): Uses ketone bodies along with glucose.

RBCs:

• Always use glucose → lactate (anaerobic glycolysis) → Cori cycle.

⚙️ Hormonal Control

Insulin:

• Promotes anabolic pathways (glycogenesis, lipogenesis, protein synthesis).

• Increases glucose uptake in muscle/adipose via GLUT-4.

Glucagon:

• Promotes catabolic pathways in liver (glycogenolysis, gluconeogenesis, lipolysis in adipose indirectly).

Epinephrine:

• Rapid response during stress/exercise — stimulates glycogenolysis (muscle and liver) and lipolysis.

? Clinical Correlation Examples

• Type 1 Diabetes Mellitus: Low/no insulin → unopposed glucagon → simultaneous gluconeogenesis, glycogenolysis, lipolysis, ketogenesis → hyperglycemia + ketoacidosis.

• Glycogen Storage Diseases: Defective glycogen breakdown impairs glucose supply in fasting.

• Carnitine deficiency: Impaired β-oxidation → hypoketotic hypoglycemia in fasting.

? High-Yield Summary for Part 1

• Metabolic integration revolves around availability of fuels and hormonal regulation.

• Fed state: Store excess fuel — glycogenesis, lipogenesis, protein synthesis.

• Fasting state: Mobilize fuel — glycogenolysis, gluconeogenesis, lipolysis.

• The liver is the central processing unit for fuel storage and release.

• Key intermediates — glucose, acetyl-CoA, and TCA cycle metabolites — link all major pathways.

? Introduction

Part 1 covered integration in the fed state and early fasting (up to ~16 hours).
Part 2 focuses on:

• Prolonged fasting / starvation (beyond 24 hours).

• Metabolic adaptations during extended food deprivation.

• Exercise metabolism and how multiple energy systems interact.

These stages show how the body conserves glucose, prioritizes brain and RBC needs, and uses fat and ketone bodies to sustain life.

? Prolonged Fasting / Starvation (≥ 24 hours)

Hormonal Profile

• Very low insulin, high glucagon, increased cortisol.

• Epinephrine remains moderately elevated.

Liver

• Glycogen stores: Depleted by ~24 hours.

• Gluconeogenesis: Becomes the sole source of glucose for blood.

  • Substrates: Glycerol (from adipose lipolysis), lactate (Cori cycle), and amino acids (mainly alanine, glutamine from muscle).

• Ketogenesis: Massive production of ketone bodies (acetoacetate, β-hydroxybutyrate) from excess acetyl-CoA from β-oxidation.

Adipose Tissue

• Lipolysis is the primary source of energy substrates (FFA + glycerol).

• FFAs → liver and muscle; glycerol → liver for gluconeogenesis.

Muscle

• Early starvation: Uses both fatty acids and ketone bodies.

• After 2–3 weeks: Muscle reduces ketone body use → spares them for the brain.

• Increases reliance on fatty acids for ATP.

Brain

• Early starvation: Uses only glucose.

• By 2–3 weeks: Adapts to use ketone bodies for up to 2/3 of energy needs — reduces demand for gluconeogenesis → spares muscle protein.

RBCs

• Still depend exclusively on glucose (anaerobic glycolysis).

• Lactate recycled to liver via the Cori cycle.

? Adaptive Advantages in Starvation

• Protein sparing: Shift of brain fuel from glucose to ketones decreases muscle proteolysis.

• Fat oxidation priority: Tissues able to use FFAs do so, conserving glucose for brain & RBCs.

? Exercise Metabolism Integration

Exercise intensity and duration determine fuel mix:

Immediate (Seconds) — ATP-CP System

• ATP already in muscle + creatine phosphate (phosphagen system).

• Anaerobic; sustains activity for ~8–10 seconds.

Short-Term (Seconds–Minutes) — Anaerobic Glycolysis

• Muscle glycogen → glucose → pyruvate → lactate.

• Rapid ATP production, but lactate accumulation leads to fatigue.

• Used in high-intensity, short-duration activity (e.g., sprinting).

Long-Term (> 2 minutes) — Aerobic Metabolism

• Initially glucose oxidation (muscle glycogen + blood glucose).

• With prolonged exercise, FFA oxidation becomes dominant fuel.

• At low–moderate intensity: Predominantly aerobic oxidation of glucose and fats.

• At very long duration: Increased reliance on FFAs and some amino acids (e.g., branched-chain amino acids).

Hormonal Changes in Exercise

• ↑ Epinephrine & norepinephrine → glycogenolysis in muscle and liver.

• ↑ Glucagon → hepatic glucose output.

• ↓ Insulin → facilitates lipolysis and hepatic glucose release.

? Clinical Correlation Examples

1. Marasmus (Prolonged Starvation)

• Deficiency of both calories and protein.

• Muscle wasting, loss of subcutaneous fat, but no edema.

2. Kwashiorkor

• Adequate calories but protein deficiency.

• Edema, fatty liver (impaired lipoprotein synthesis), poor wound healing.

3. Uncontrolled Type 1 Diabetes Mellitus

• Metabolic profile mimics prolonged starvation despite nutrient abundance — high ketogenesis, gluconeogenesis, lipolysis.

4. McArdle Disease (GSD V)

• Deficient muscle glycogen phosphorylase → exercise intolerance, no lactate rise, reliance on blood glucose and FFAs.

? High-Yield Summary – Starvation & Exercise

• Starvation sequence:

  • 0–4 hrs: Fed state (insulin dominant).

  • 4–16 hrs: Early fasting (glycogenolysis + gluconeogenesis).

  • 24 hrs: Gluconeogenesis + increasing ketogenesis.

  • Weeks: Brain shifts to ketones → protein sparing.

• Exercise sequence:

  • Immediate: ATP-CP system.

  • Short term: Anaerobic glycolysis.

  • Long term: Aerobic metabolism, shift to fat oxidation.

• Key integration concept: Hormones direct fuel selection; tissues coordinate to preserve glucose for brain and RBCs while maximizing fat usage in prolonged fasting and endurance exercise.